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are heparin compounds having anticoagulant activity , 
including a binding affinity to antithrombin and an anti - Xa 
activity , but no detectable anti - lla activity . Additionally , 
provided are synthetic , low - molecular weight heparin com 
pounds with reversible anticoagulant activity , where the 
anticoagulant activity is reversible by protamine . 
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REVERSIBLE HEPARIN MOLECULES AND eration LMW heparin , and the United States approval of a 
METHODS OF MAKING AND USING THE generic LMW heparin , M - Enoxaparin . 
SAME UF heparin is isolated from porcine intestine or bovine 
lung , and LMW heparins are prepared through the chemical 
CROSS REFERENCE TO RELATED 5 or enzymatic degradation of this animal - sourced UF hepa 
APPLICATION rin . A worldwide outbreak of contaminated heparin has 
raised concerns over the reliability and safety of animal 
This application claims the benefit of U . S . Provisional sourced heparins and LMW heparins ( Guerrini et al . , 2008 ; 
Patent Application Ser . No . 61 / 835 , 875 , filed Jun . 17 , 2013 , Liu et al . , 2009 ) . As a result , a cost - effective method for 
the disclosure of which is incorporated herein by reference 10 preparing new synthetic heparins is highly desirable ( Peter 
in its entirety . son et al . , 2009 ) . 
GRANT STATEMENT SUMMARY 
15 This Summary lists several embodiments of the presently This invention was made with government support under disclosed subject matter , and in many cases lists variations Grant No . 1R01HL094463 awarded by the National Insti and permutations of these embodiments . This Summary is tutes of Health . The government has certain rights in the merely exemplary of the numerous and varied embodiments . invention . Mention of one or more representative features of a given 
20 embodiment is likewise exemplary . Such an embodiment TECHNICAL FIELD can typically exist with or without the feature ( s ) mentioned ; 
likewise , those features can be applied to other embodiments 
The subject matter disclosed herein relates generally to of the presently disclosed subject matter , whether listed in 
synthesis of heparin compounds . More particularly , the this Summary or not . To avoid excessive repetition , this 
subject matter disclosed herein relates to chemoenzymatic 25 Summary does not list or suggest all possible combinations 
synthesis of structurally homogeneous low molecular of such features . 
weight heparins that have a reversible anticoagulant activity . In some embodiments methods of synthesizing heparin 
compounds are provided . Such methods can in some 
BACKGROUND embodiments comprise providing a saccharide substrate , 
30 elongating the saccharide substrate to a saccharide of a 
Heparan sulfate ( HS ) is a ubiquitous component of the desired or predetermined length , performing an epimeriza 
cell surface and extracellular matrix . It regulates a wide tion reaction , and performing one or more sulfation reac 
range of physiologic and pathophysiologic functions , tions , whereby a heparin compound is synthesized . In some 
including embryonic development and blood coagulation , embodiments , the elongation step can comprise employing 
and can facilitate viral infection ( Esko and Selleck ( 2002 ) 35 a glycosyl transferase . In some embodiments , the glycosyl 
Annu . Rev . Biochem . 71 , 435 - 471 ; Liu and Thorp ( 2002 ) transferase is selected from the group consisting of N - acetyl 
Med . Res . Rev . 22 , 1 - 25 ) . HS exerts its biological effects by glucosaminyl transferase of E . coli K5 ( KfiA ) and / or hepa 
interacting with the specific proteins involved in a given rosan synthase - 2 ( pmHS2 ) from Pasteurella multocida . In 
process ( Capila and Lindhardt ( 2002 ) Angew . Chem . Int Ed . some embodiments , the elongation step can comprise 
41 , 390 - 412 ) . HS is a highly charged polysaccharide com - 40 employing one or more monosaccharides selected from the 
prising 1 4 - linked glucosamine and glucuronic / iduronic group consisting of : glucuronic acid ( GICUA ) , N - acetylated 
acid units that contain both N - and O - sulfo groups . Unique glucosamine ( GlcNAc ) , and N - trifluoroacetyl glucosamine 
saccharide sequences within HS can determine the specific - ( GlcNTFA ) . 
ity of the binding of HS to its target proteins ( Linhardt In some embodiments , methods of synthesizing heparin ( 2003 ) J . Med . Chem . 46 , 2551 - 2564 ) . Heparin , a special - 45 compounds can further comprise converting an N - sul 
ized form of HS , is a commonly used anticoagulant drug . fotransferase substrate residue on the hexasaccharide or 
Thus , new methods for the synthesis of heparin compounds heptasaccharide to a N - sulfo glucosamine ( GlcNS ) residue , 
and HS attract considerable interest for those developing comprising employing N - sulfotransferase ( NST ) and 
anticoagulant and other HS - related drugs having improved 3 ' - phosphoadenosine 5 - phosphosulfate ( PAPS ) . In some 
pharmacological effects . 50 embodiments , methods of synthesizing heparin compounds 
Heparin has been successfully used as an anticoagulant can further comprise employing a base in one or more 
drug for over 50 years ( Mackman , 2008 ) . It is currently converting reactions , wherein the base is optionally a 
marketed in three forms : unfractionated ( UF ) heparin lithium hydroxide or a mixture of triethylamine , CH2OH , 
( MWQvo ~ 14000 Da ) ; a low molecular weight heparin and / or H , O . 
( MWave ~ 6000 Da ) ; and the synthetic ULMW heparin 55 In some embodiments , the epimerization reaction com 
pentasaccharide ARIXTRA® ( MW 1508 . 3 Da ) . UF heparin prises employing Cz - epimerase ( Cz - epi ) . In some embodi 
is used in surgery and kidney dialysis due to its relatively ments , the sulfation reaction comprises employing 2 - 0 
short half - life and its safety for renal impaired patients sulfotransferase ( 2 - OST ) . In some embodiments , the ( Hirsh et al . , 2007 ) . LMW heparins and the ULMW heparin sulfation reaction comprises employing 6 - O - sulfotrans 
ARIXTRA® , introduced over a decade ago , have played an 60 ferase ( 6 - OST ) , optionally 6 - OST - 1 and / or 6 - OST - 3 . In 
increasingly important role for preventing venous thrombo - some embodiments , the sulfation reaction comprises 
sis among high risk patients ( Tohu et al , 2004 ; Weitz , 2010 ) employing 3 - O - sulfotransferase ( 3 - OST ) , optionally 
because of their more predictable anticoagulant dose , long 3 - OST - 1 and / or 3 - OST - 5 . 
half - lives and their reduced risk of osteoporosis ( Weitz and In some embodiments , the methods of synthesizing hepa 
Linkins , 2007 ) . Recent research on LMW heparin has 65 rin compounds can have a yield of greater than 30 % . In some 
resulted in the European approval of Bemiparin sodium embodiments , provided herein are heparin compounds syn 
( Martinez - Gonzalez and Rodriguez , 2010 ) , a second - gen - thesized by the disclosed methods of synthesis . In some 
V2 
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embodiments , the heparin compounds can have a molecular ine 5 ' - phosphosulfate ( PAPS ) , converting N - trifluoroacetyl 
weight ranging from about 1500 daltons ( Da ) to about 6000 glucosamine ( GlcNTFA ) residue ( s ) on the heptasaccharide 
Da . In some embodiments , the heparin compounds can have to N - sulfo glucosamine ( GlcNS ) residues using N - sul 
anticoagulant activity . In some embodiments , the heparin fotransferase ( NST ) , 3 ' - phosphoadenosine 5 ' - phosphosul 
compounds can have a binding affinity to antithrombin 5 fate ( PAPS ) , and a base , optionally lithium hydroxide , 
ranging from about 5 nM to about 30 nM . In some embodi - sulfating the octasaccharide using a 6 - O - sulfotransferase 
ments , the heparin compounds can have anti - Xa activity ( 6 - OST ) , optionally 6 - O - sulfotransferase 1 and / or 3 
ranging from about 10 ngml - to about 40 ngml - - IC50 under ( 6 - OST - 1 and / or 6 - OST - 3 ) , and 3 ' - phosphoadenosine 
conditions described herein . In some embodiments , the 5 ' - phosphosulfate ( PAPS ) , and sulfating the octasaccharide 
heparin compounds can have no detectable anti - lla activity . 10 using a 3 - O - sulfotransferase ( 3 - OST ) , optionally 3 - O - sul 
In some embodiments , provided herein are methods of fotransferase 1 ( 3 - OST - 1 ) , and 3 ' - phosphoadenosine 
synthesizing a heparin compound , comprising providing a 5 - phosphosulfate ( PAPS ) , wherein a heparin compound is 
monosaccharide substrate , elongating the monosaccharide synthesized . 
substrate to a hexasaccharide using enzymes N - acetyl glu In some embodiments , the heparin compound produced 
cosaminyl transferase and heparosan synthase - 2 , and sub - 15 by this method has anticoagulant activity . In some embodi 
strates glucuronic acid ( GlCUA ) and N - trifluoroacetyl glu - ments , the heparin compound has a binding affinity to 
cosamine ( GlcNTFA ) , converting N - trifluoroacetyl antithrombin ranging from about 5 nM to about 11 nM . In 
glucosamine ( GlcNTFA ) residue ( s ) on the heptasaccharide some embodiments , the heparin compound has anti - Xa 
to N - sulfo glucosamine ( GlcNS ) residue ( s ) using N - sul - activity of about 12 ngml - ICs to about 22 ngml - - ICs , 
fotransferase ( NST ) , 3 ' - phosphoadenosine 5 ' - phosphosul - 20 optionally about 17 ngml - - IC50 , under conditions described 
fate ( PAPS ) , and a base , epimerizing the hexasaccharide herein . 
using Cz - epimerase ( C3 - epi ) , sulfating the hexasaccharide In some embodiments , provided herein are methods of 
using 2 - 0 - sulfotransferase ( 2 - OST ) and 3 ' - phosphoadenos - synthesizing a heparin compound , comprising providing a 
ine 5 ' - phosphosulfate ( PAPS ) , sulfating the hexasaccharide monosaccharide substrate , elongating the monosaccharide 
using a 6 - O - sulfotransferase ( 6 - OST ) , optionally 6 - O - sul - 25 substrate to a hexasaccharide using enzymes N - acetyl glu 
fotransferase 1 and / or 3 ( 6 - OST - 1 and / or 6 - OST - 3 ) , and cosaminyl transferase and heparosan synthase - 2 , and sub 
3 ' - phosphoadenosine 5 ' - phosphosulfate ( PAPS ) , and sulfat - strates glucuronic acid ( GlCUA ) and N - trifluoroacetyl glu 
ing the hexasaccharide using a 3 - O - sulfotransferase cosamine ( GlcNTFA ) , converting N - trifluoroacetyl 
( 3 - OST ) , optionally 3 - 0 - sulfotransferase 1 ( 3 - OST - 1 ) , and glucosamine ( GlcNTFA ) residue ( s ) on the heptasaccharide 
3 ' - phosphoadenosine 5 ' - phosphosulfate ( PAPS ) , wherein a 30 to N - sulfo glucosamine ( GlcNS ) residues using N - sul 
heparin compound is synthesized . In some embodiments , the fotransferase ( NST ) , 3 - phosphoadenosine 5 ' - phosphosul 
monosaccharide substrate is 1 - 0 - ( paranitrophenyl ) glu - fate ( PAPS ) , and a base , optionally lithium hydroxide , 
curonide ( GlcA - pnp ) . epimerizing the hexasaccharide using Cz - epimerase ( CG 
In some embodiments , the heparin compound produced epi ) , sulfating the hexasaccharide using 2 - 0 - sulfotrans 
by this method has anticoagulant activity . In some embodi - 35 ferase ( 2 - OST ) and 3 ' - phosphoadenosine 5 ' - phosphosulfate 
ments , the heparin compound has a binding affinity to ( PAPS ) , converting N - trifluoroacetyl glucosamine ( G1 
antithrombin ranging from about 5 nM to about 9 nM . In cNTFA ) residue ( s ) on the heptasaccharide to N - sulfo glu 
some embodiments , the heparin compound has anti - Xa cosamine ( GlcNS ) residues using N - sulfotransferase ( NST ) , 
activity of about 10 ngml - - ICs , to about 20 ngm1 - IC50 , 3 ' - phosphoadenosine 5 ' - phosphosulfate ( PAPS ) , and a base , 
optionally about 14 ngml - ? IC50 , under conditions described 40 optionally lithium hydroxide , elongating the hexasaccharide 
herein . substrate to a heptasaccharide using heparosan synthase - 2 
In some embodiments , provided herein are methods of and the substrate glucuronic acid ( GICUA ) , elongating the 
synthesizing a heparin compound , comprising providing a heptasaccharide substrate to a octasaccharide using N - acetyl 
monosaccharide substrate , elongating the monosaccharide glucosaminyl transferase and substrate and N - trifluoroacetyl 
substrate to a hexasaccharide using enzymes N - acetyl glu - 45 glucosamine ( GlcNTFA ) , epimerizing the octasaccharide 
cosaminyl transferase and heparosan synthase - 2 , and sub - using Cz - epimerase ( Cz - epi ) , sulfating the octasaccharide 
strates glucuronic acid ( GICUA ) and N - trifluoroacetyl glu - using 2 - O - sulfotransferase ( 2 - OST ) and 3 ' - phosphoadenos 
cosamine ( GlcNTFA ) , converting N - trifluoroacetyl ine 5 ' - phosphosulfate ( PAPS ) , converting N - trifluoroacetyl 
glucosamine ( GlcNTFA ) residue ( s ) on the heptasaccharide glucosamine ( GlcNTFA ) residue ( s ) on the heptasaccharide 
to N - sulfo glucosamine ( GlcNS ) residues using N - sul - 50 to N - sulfo glucosamine ( GlcNS ) residues using N - sul 
fotransferase ( NST ) , 3 ' - phosphoadenosine 5 ' - phosphosul - fotransferase ( NST ) , 3 ' - phosphoadenosine 5 ' - phosphosul 
fate ( PAPS ) , and a base , optionally lithium hydroxide , fate ( PAPS ) , a base , optionally lithium hydroxide , elongat 
epimerizing the hexasaccharide using Cz - epimerase ( Cs ing the octasaccharide substrate to a decasaccharide using 
epi ) , sulfating the hexasaccharide using 2 - O - sulfotrans - heparosan synthase - 2 and N - acetyl glucosaminyl trans 
ferase ( 2 - OST ) and 3 ' - phosphoadenosine 5 ' - phosphosulfate 55 ferase , and using the substrates glucuronic acid ( GICUA ) and ( PAPS ) , converting N - trifluoroacetyl glucosamine ( Gl N - trifluoroacetyl glucosamine ( GlcNTFA ) , epimerizing the 
cNTFA ) residue ( s ) on the heptasaccharide to N - sulfo glu - decasaccharide using C3 - epimerase ( Cs - epi ) , sulfating the 
cosamine ( GlcNS ) residues using N - sulfotransferase ( NST ) , decasaccharide using 2 - O - sulfotransferase ( 2 - OST ) and 3 - phosphoadenosine 5 ' - phosphosulfate ( PAPS ) , and a base , 3 ' - phosphoadenosine 5 ' - phosphosulfate ( PAPS ) , converting 
optionally lithium hydroxide , elongating the hexasaccharide 60 N - trifluoroacetyl glucosamine ( GlcNTFA ) residue ( s ) on the 
substrate to a heptasaccharide using heparosan synthase - 2 decasaccharide to N - sulfo glucosamine ( GlcNS ) residues 
and the substrate glucuronic acid ( GlCUA ) , elongating the using N - sulfotransferase ( NST ) , 3 ' - phosphoadenosine 
heptasaccharide substrate to a octasaccharide using N - acetyl 5 - phosphosulfate ( PAPS ) , and a base , optionally lithium 
glucosaminyl transferase and substrate and N - trifluoroacetyl h ydroxide , sulfating the decasaccharide using a 6 - 0 - sul 
glucosamine ( GlcNTFA ) , epimerizing the octasaccharide 65 fotransferase ( 6 - OST ) , optionally 6 - 0 - sulfotransferase 1 
using Cz - epimerase ( Cz - epi ) , sulfating the octasaccharide and / or 3 ( 6 - OST - 1 and / or 6 - OST - 3 ) , and 3 ' - phosphoadenos 
using 2 - 0 - sulfotransferase ( 2 - OST ) and 3 ' - phosphoadenos - ine 5 ' - phosphosulfate ( PAPS ) , and sulfating the decasaccha 
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ride using a 3 - O - sulfotransferase ( 3 - OST ) , optionally 3 - 0 - ( PAPS ) , converting N - trifluoroacetyl glucosamine ( G1 
sulfotransferase 1 ( 3 - OST - 1 ) , and 3 ' - phosphoadenosine CNTFA ) residue ( s ) on the heptasaccharide to N - sulfo glu 
5 ' - phosphosulfate ( PAPS ) , wherein a heparin compound is cosamine ( GlcNS ) residues using N - sulfotransferase ( NST ) , 
synthesized . 3 ' - phosphoadenosine 5 ' - phosphosulfate ( PAPS ) , and a base , 
In some embodiments , the heparin compound produced 5 optionally lithium hydroxide , elongating the decasaccharide 
by this method has anticoagulant activity . In some embodi substrate to a dodecasaccharide using heparosan synthase - 2 
ments , the heparin compound has a binding affinity to and N - acetyl glucosaminyl transferase , and using the sub 
strates glucuronic acid ( GICUA ) and N - trifluoroacetyl glu antithrombin ranging from about 4 nM to about 6 nM . In cosamine ( GlcNTFA ) , epimerizing the dodecasaccharide some embodiments , the heparin compound has anti - Xa 
activity of about 10 ngml - ? IC50 to about 20 ngml - ? IC50 , 10 using Cz - epimerase ( Cz - epi ) , sulfating the dodecasaccharide using 2 - 0 - sulfotransferase ( 2 - OST ) and 3 ' - phosphoadenos optionally about 15 ngm1 - ICso , under conditions described ine 5 ' - phosphosulfate ( PAPS ) , sulfating the dodecasaccha herein . In some embodiments , the heparin compound is ride using a 6 - 0 - sulfotransferase ( 6 - OST ) , optionally 6 - 0 
susceptible to Stablin - 2 mediated endocytosis , wherein a sulfotransferase 1 and / or 3 ( 6 - OST - 1 and / or 6 - OST - 3 ) , and heparin compound that is endocytosed at a rate of 15 % or 3 ' - phosphoadenosine 5 ' - phosphosulfate ( PAPS ) , and sulfat 
more is susceptible to Stablin - 2 mediated endocytosis . 15 ing the dodecasaccharide using a 3 - O - sulfotransferase 
In some embodiments , provided herein are methods of ( 3 - OST ) , optionally 3 - O - sulfotransferase 1 ( 3 - OST - 1 ) , and 
synthesizing a heparin compound , comprising providing a 3 ' - phosphoadenosine 5 - phosphosulfate ( PAPS ) , wherein a 
monosaccharide substrate , elongating the monosaccharide heparin compound is synthesized . 
substrate to a hexasaccharide using enzymes N - acetyl glu In some embodiments , the heparin compound produced 
cosaminyl transferase and heparosan synthase - 2 , and sub - 20 by this method has anticoagulant activity . In some embodi 
strates glucuronic acid ( GlCUA ) and N - trifluoroacetyl glu ments , the heparin compound has a binding affinity to 
cosamine ( GlcNTFA ) , converting N - trifluoroacetyl antithrombin ranging from about 23 nM to about 37 nM . In glucosamine ( GlcNTFA ) residue ( s ) on the heptasaccharide some embodiments , the heparin compound has anti - Xa to N - sulfo glucosamine ( GlcNS ) residues using N - sul activity of about 25 ngml - ? IC50 to about 45 ngml - ? IC50 , fotransferase ( NST ) , 3 ' - phosphoadenosine 5 ' - phosphosul 
fate ( PAPS ) , and a base , optionally lithium hydroxide , 25 optionally about 35 ngml - ? IC50 , under conditions described herein . In some embodiments , the heparin compound is epimerizing the hexasaccharide using Cz - epimerase ( Cs 
epi ) , sulfating the hexasaccharide using 2 - 0 - sulfotrans susceptible to Stablin - 2 mediated endocytosis at a rate of 
ferase ( 2 - OST ) and 3 ' - phosphoadenosine 5 ' - phosphosulfate 15 % or more . In some embodiments , the anticoagulant ( PAPS ) , converting N - trifluoroacetyl glucosamine ( G1 activity of the heparin compound is partially reversible by 
CNTFA ) residue ( s ) on the heptasaccharide to N - sulfo glu - 30 protamine , wherein a heparin compound having anticoagu 
cosamine ( GlcNS ) residues using N - sulfotransferase ( NST ) , lant activity that is reversible at a rate of 50 % or more in the 3 ' - phosphoadenosine 5 ' - phosphosulfate ( PAPS ) , and a base , presence of 20 ug / ml or less of protamine is partially 
optionally lithium hydroxide , elongating the hexasaccharide reversible . 
substrate to a heptasaccharide using heparosan synthase - 2 In some embodiments , provided herein are methods of 
and the substrate glucuronic acid ( GIPUA ) , elongating the 35 synthesizing a heparin compound , comprising providing a 
heptasaccharide substrate to a octasaccharide using N - acetyl monosaccharide substrate , elongating the monosaccharide 
glucosaminyl transferase and substrate and N - trifluoroacetyl substrate to a hexasaccharide using enzymes N - acetyl glu 
glucosamine ( GlcNTFA ) , epimerizing the octasaccharide cosaminyl transferase and heparosan synthase - 2 , and sub 
using Co - epimerase ( CG - epi ) , sulfating the octasaccharide strates glucuronic acid ( GICUA ) and N - trifluoroacetyl glu 
using 2 - 0 - sulfotransferase ( 2 - OST ) and 3 ' - phosphoadenos - 40 cosamine ( GlcNTFA ) , converting N - trifluoroacetyl 
ine 5 ' - phosphosulfate ( PAPS ) , converting N - trifluoroacetyl glucosamine ( GlcNTFA ) residue ( s ) on the heptasaccharide 
glucosamine ( GlcNTFA ) residue ( s ) on the heptasaccharide to N - sulfo glucosamine ( GlcNS ) residues using N - sul 
to N - sulfo glucosamine ( GlcNS ) residues using N - sul fotransferase ( NST ) , 3 ' - phosphoadenosine 5 ' - phosphosul 
fotransferase ( NST ) , 3 ' - phosphoadenosine 5 ' - phosphosul fate ( PAPS ) , and a base , optionally lithium hydroxide , 
fate ( PAPS ) , and a base , optionally lithium hydroxide , us epimerizing the hexasaccharide using C5 - epimerase ( Cs 
elongating the octasaccharide substrate to a decasaccharide » epi ) , sulfating the hexasaccharide using 2 - O - sulfotrans 
using heparosan synthase - 2 and N - acetyl glucosaminyl ferase ( 2 - OST ) and 3 ' - phosphoadenosine 5 ' - phosphosulfate 
transferase , and using the substrates glucuronic acid ( G1 ( PAPS ) , converting N - trifluoroacetyl glucosamine ( Gl 
CUA ) and N - trifluoroacetyl glucosamine ( GlcNTFA ) , CNTFA ) residue ( s ) on the heptasaccharide to N - sulfo glu 
epimerizing the decasaccharide using Cz - epimerase ( C - cosamine ( GlcNS ) residues using N - sulfotransferase ( NST ) , 
epi ) , sulfating the decasaccharide using 2 - 0 - sulfotransferase 50 3 ' - phosphoadenosine 5 ' - phosphosulfate ( PAPS ) , and a base , ( 2 - OST ) and 3 - phosphoadenosine 5 ' - phosphosulfate optionally lithium hydroxide , to provide the hexasaccharide : 
1 
CH2OSO3H 
CH2OSO3H MS , OH 
O 
COOH 
OH CH20803H COOH OSOH NHSO3H 
- 0 . O Doob NHSO3H OSO3H OH ?? NHSO3H OH 
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where MS means monosaccharide , elongating the hexasac embodiments , the subject can suffer from venous thrombo 
charide substrate to a heptasaccharide using heparosan syn embolism . In some embodiments , the subject can be renal 
thase - 2 and the substrate glucuronic acid ( GICUA ) , elongat - impaired . In some embodiments , the subject can be a human 
ing the heptasaccharide substrate to a octasaccharide using subject . 
N - acetyl glucosaminyl transferase and substrate and N - tri - 5 In some embodiments , provided herein are methods of 
fluoroacetyl glucosamine ( GlcNTFA ) , epimerizing the treating a subject in need of anticoagulant therapy , the 
octasaccharide using Co - epimerase ( Cs - epi ) , sulfating the method comprising providing a subject in need of antico 
octasaccharide using 2 - 0 - sulfotransferase ( 2 - OST ) and agulant therapy , administering to the subject a heparin 
3 ' - phosphoadenosine 5 ' - phosphosulfate ( PAPS ) , converting compound having anticoagulant activity , monitoring the 
N - trifluoroacetyl glucosamine ( GlcNTFA ) residue ( s ) on the 10 subject for heparin - induced thrombocytopenia , and admin 
heptasaccharide to N - sulfo glucosamine ( GlcNS ) residues istering to the subject an antidote to reverse the anticoagu 
using N - sulfotransferase ( NST ) , 3 ' - phosphoadenosine lant activity of the heparin compound if the subject suffers 
5 ' - phosphosulfate ( PAPS ) , and a base , optionally lithium from heparin - induced thrombocytopenia . In some embodi 
hydroxide , elongating the octasaccharide substrate to a ments , the subject suffers from venous thromboembolism . In 
decasaccharide using heparosan synthase - 2 and N - acetyl 15 some embodiments , the subject is renal - impaired . In some 
glucosaminyl transferase , and using the substrates glu - embodiments , the subject is a human subject . In some 
curonic acid ( GlcUA ) and N - trifluoroacetyl glucosamine embodiments , the antidote to reverse the anticoagulant 
( GlcNTFA ) , epimerizing the decasaccharide using C5 - epi - activity of the heparin compound is protamine . 
merase ( C5 - epi ) , sulfating the decasaccharide using 2 - 0 . In some embodiments , provided herein are synthetic , 
sulfotransferase ( 2 - OST ) and 3 ' - phosphoadenosine 5 ' - phos - 20 low - molecular weight heparin compounds with reversible 
phosulfate ( PAPS ) , converting N - trifluoroacetyl anticoagulant activity , wherein the anticoagulant activity of 
glucosamine ( GlcNTFA ) residue ( s ) on the heptasaccharide the heparin compound is reversible by protamine , wherein 
to N - sulfo glucosamine ( GlcNS ) residues using N - sul - the anticoagulant activity is reversed by about 50 % or more 
fotransferase ( NST ) , 3 ' - phosphoadenosine 5 ' - phosphosul - in the presence of 1 ug / ml of protamine . 
fate ( PAPS ) , and a base , optionally lithium hydroxide , 25 In some embodiments , provided herein are synthetic , 
elongating the decasaccharide substrate to a dodecasaccha - low - molecular weight heparin compounds susceptible to 
ride using heparosan synthase - 2 and N - acetyl glucosaminyl liver - mediated clearance from circulation . In some embodi 
transferase , and using the substrates glucuronic acid ( Gl - ments , the heparin compound can be susceptible to Stablin - 2 
CUA ) and N - trifluoroacetyl glucosamine ( GlcNTFA ) , mediated endocytosis at a rate of 15 % or more . In some 
epimerizing the dodecasaccharide using Cg - epimerase ( Cs - 30 embodiments , the heparin compound is suitable for admin 
epi ) , sulfating the dodecasaccharide using 2 - 0 - sulfotrans - istration to renal - impaired patients . In some embodiments , 
ferase ( 2 - OST ) and 3 ' - phosphoadenosine 5 ' - phosphosulfate the heparin compound comprises at least one 3 - 0 sulfate . In 
( PAPS ) , sulfating the dodecasaccharide using a 6 - O - sul - some embodiments , the heparin compound is a dodecamer . 
fotransferase ( 6 - OST ) , Optionally 6 - O - sulfotransferase 1 Accordingly , it is an object of the presently disclosed 
and / or 3 ( 6 - OST - 1 and / or 6 - OST - 3 ) , and 3 ' - phosphoadenos - 35 subject to provide low molecular weight heparins that have 
ine 5 ' - phosphosulfate ( PAPS ) , sulfating the dodecasaccha - a reversible anticoagulant activity and methods for synthe 
ride using a 3 - O - sulfotransferase ( 3 - OST ) , optionally 3 - 0 sizing the same . 
sulfotransferase 1 ( 3 - OST - 1 ) , and 3 ' - phosphoadenosine An object of the presently disclosed subject matter having 
5 ' - phosphosulfate ( PAPS ) , and sulfating the dodecasaccha - been stated hereinabove , and which is achieved in whole or 
ride using a 3 - O - sulfotransferase ( 3 - OST ) , optionally a 40 in part by the presently disclosed subject matter , other 
3 - 0 - sulfotransferase - 5 ( 3 - OST - 5 ) , and 3 - phosphoadenosine objects will become evident as the description proceeds 
5 ' - phosphosulfate ( PAPS ) , wherein a heparin compound is when taken in connection with the accompanying drawings 
synthesized . and examples as best described hereinbelow . 
In some embodiments , the heparin compound produced 
by this method has anticoagulant activity . In some embodi - 45 BRIEF DESCRIPTION OF THE DRAWINGS 
ments , the heparin compound has a binding affinity to 
antithrombin ranging from about 12 nM to about 44 nM . In The presently disclosed subject matter can be better 
some embodiments , the heparin compound has anti - Xa understood by referring to the following figures . The com 
activity of about 10 ngml - 1 ICs to about 30 ngml - ? ICso , ponents in the figures are not necessarily to scale , emphasis 
optionally about 21 ngml - ? IC50 , under conditions described 50 instead being placed upon illustrating the principles of the 
herein . In some embodiments , the heparin compound is presently disclosed subject matter ( often schematically ) . In 
susceptible to Stablin - 2 mediated endocytosis at a rate of the figures , like reference numerals designate corresponding 
15 % or more . In some embodiments , the anticoagulant parts throughout the different views . A further understanding 
activity of the heparin compound is reversible by protamine of the presently disclosed subject matter can be obtained by 
at a rate of 50 % or more in the presence of 20 ug / ml or less 55 reference to embodiments set forth in the illustrations of the 
of protamine . accompanying drawings . Although the illustrated embodi 
In some embodiments , provided herein are methods of ments are merely exemplary of systems for carrying out the 
treating a subject , the methods comprising providing a presently disclosed subject matter , both the organization and 
subject to be treated , administering to the subject a heparin method of operation of the presently disclosed subject 
compound having anticoagulant activity , wherein the hepa - 60 matter , in general , together with further objectives and 
rin compound comprises a heparin compound as disclosed advantages thereof , may be more easily understood by 
herein , or wherein the heparin compound comprises a syn - reference to the drawings and the following description . The 
thetic , low - molecular weight heparin compound with revers drawings are not intended to limit the scope of this presently 
ible anticoagulant activity , wherein the anticoagulant activ disclosed subject matter , which is set forth with particularity 
ity of the heparin compound is reversible by protamine , 65 in the claims as appended or as subsequently amended , but 
wherein the anticoagulant activity is reversed by about 50 % merely to clarify and exemplify the presently disclosed 
or more in the presence of 1 ug / ml of protamine . In some subject matter . 
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For a more complete understanding of the presently or percentage is meant to encompass variations of in some 
disclosed subject matter , reference is now made to the embodiments + 20 % , in some embodiments + 10 % , in some 
following drawings in which : embodiments = 5 % , in some embodiments = 1 % , in some 
FIGS . 1A - 11 illustrate the chemical structures of Com - embodiments 0 . 5 % , and in some embodiments + 0 . 1 % from 
pounds 1 - 9 ( FIG . 1A , Compound 1 ; FIG . 1B , Compound 2 ; 5 the specified amount , as such variations are appropriate to 
FIG . 1C , Compound 3 ; FIG . 1D , Compound 4 ; FIG . 1E , perform the disclosed methods . Accordingly , unless indi 
Compound 5 ; FIG . 1F , Compound 6 ; FIG . 16 , Compound 7 ; cated to the contrary , the numerical parameters set forth in 
FIG . 1H , Compound 8 ; FIG . 11 , Compound 9 ) ; this specification of the presently disclosed subject matter 
FIG . 2 is schematic illustration of the synthesis of Com - are approximations that can vary depending upon the desired 
pound 1 and 6 ; 10 properties sought to be obtained by the presently disclosed 
FIG . 3 is a schematic illustration of the synthesis of subject matter . 
synthetic LMWHs as disclosed herein . The synthesis can in As used herein , the term “ and / or ” when used in the 
some aspects be initiated from a hexasaccharide ( Compound context of a listing of entities , refers to the entities being 
6 ) , which can be converted to an octasaccharide ( Compound present singly or in combination . Thus , for example , the 
7 ) , decasaccharide ( Compound 8 ) and dodecasaccharide 15 phrase “ A , B , C , and / or D ” includes A , B , C , and D ( Compound 9 ) to synthesize Compounds 2 , 3 , and 4 , respec - individually , but also includes any and all combinations and 
tively . The conversion of Compound 4 to 5 can be achieved subcombinations of A , B , C , and D . 
by 3 - OST - 5 modification ; The term " comprising ” , which is synonymous with 
FIGS . 4A - 4D are graphical depictions of the data for the “ including , " " containing , " or " characterized by ” is inclusive 
determination of the clearance , anti - FXa activity and sensi - 20 or open - ended and does not exclude additional , unrecited 
tivity to protamine neutralization of synthetic LMWHs . FIG . elements or method steps . “ Comprising " is a term of art used 
4A is a histogram of the percentage of 35S - labeled synthetic in claim language which means that the named elements are 
LMWHs that was retained in the liver in a mouse model . In present , but other elements can be added and still form a 
comparison to compound 1 , all tested compounds , with the Compound or method within the scope of the claim . 
exception of compound 2 and enoxaparin , showed signifi - 25 As used herein , the phrase “ consisting of excludes any 
cantly higher retention in liver ( * * * * P < 0 . 0001 ) . FIG . 4B element , step , or ingredient not specified in the claim . When 
plots FXa activity of synthetic LMWHs in the presence of the phrase " consists of " appears in a clause of the body of 
different concentrations of protamine under in vitro condi - a claim , rather than immediately following the preamble , it 
tions . FIG . 4C is a histogram of ex vivo reversibility of limits only the element set forth in that clause ; other ele 
anti - FXa activity by protamine . The inhibition of FXa 30 ments are not excluded from the claim as a whole . 
activity by the test compounds was significantly affected in As used herein , the phrase " consisting essentially of ” 
the presence of protamine ( * P < 0 . 05 and * * * * P < 0 . 0001 ) . limits the scope of a claim to the specified materials or steps , 
Data presented in FIGS . 4A - 4C are the average of three to plus those that do not materially affect the basic and novel 
five determinations - s . d . FIG . 4D plots the effect of Com - characteristic ( s ) of the claimed subject matter . 
pound 5 and protamine on tail - bleeding time after tail 35 With respect to the terms “ comprising ” , “ consisting of ” , 
transection . Protamine significantly shortened the primary and “ consisting essentially of ” , where one of these three 
bleeding time ( * * P < 0 . 01 ) that was induced by compound 5 . terms is used herein , the presently disclosed and claimed 
Each data point represents the measured value from an subject matter can include the use of either of the other two 
individual mouse in the test group ; terms . 
FIG . 5 is a histogram of endocytosis of 35S - labeled 40 As used herein , the terms " heparins " , " heparin com 
synthetic LMWHs in Flp - In - 293 cells . The cells were stably pound ” , “ HS ” , “ HS - like compound ” , and “ HS - like mol 
transfected with the plasmid expressing the Stabilin - 2 recep - ecule ” are intended to refer to synthetically sulfated poly 
tor ( 190 - HARE ) . The internalization value was calculated saccharides possessing one or more structural and / or by subtracting the nonspecific internalization background functional properties of heparan sulfates . In some embodi 
from the total internalization of a 35S - labeled Compound . 45 ments , heparin compounds can contain glucuronic acid or 
The background was determined by mixing the 35S - labeled iduronic acid and glucosamine with or without sulfo groups . 
Compound with at least 100 - fold molecular excess of unla As such , heparin compounds include , but are not limited to , 
beled UFH . All tested compounds , when compared with synthetic HSs , sulfated polysaccharides and heparins . 
Compound 1 , have significantly higher tendency to endo - II . Abbreviations 
cytosis ( * * * * = p < 0 . 0001 ) ; 50 HS heparan sulfate 
FIG . 6 is a line chart of anti - Xa activity of Compounds LMWH low molecular weight heparin 
1 - 5 , enoxaparin and UFH . NST N - sulfotransferase 
PmHS2 heparosan synthase 2 from Pasteurella multocida 
DETAILED DESCRIPTION KfiA N - acetylglucosaminyl transferase from E . coli K5 
55 strain 
Throughout the specification and claims , a given chemical Cg - epi glucuronyl C5 - epimerase 
formula or name shall encompass all optical isomers and 2 - OST 2 - O - sulfotransferase 
stereoisomers , as well as racemic mixtures where such 6 - OSTS 6 - O - sulfotransferase isoform 1 and isoform 3 
isomers and mixtures exist . 3 - OST - 1 3 - O - sulfotransferase isoform 1 
I . Definitions 3 - OST - 5 3 - O - sulfotransferase isoform 5 
Unless otherwise indicated , all numbers expressing quan NTFA N - trifluoroacetyl 
tities of ingredients , reaction conditions , and so forth used in GlcNTFA N - trifluoroacetylated glucosamine 
the specification of the presently disclosed subject matter are GlcA glucuronic acid 
to be understood as being modified in all instances by the Ido A2S 2 - 0 - sulfated iduronic acid 
term " about ” . The term “ about ” , as used herein when 65 GlcNS N - sulfoglucosamine 
referring to a measurable value such as an amount of mass , GlcNAc N - acetylated glucosamine 
weight , time , volume , temperature , pressure , concentration UFH Unfractionated heparin 
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III . General Considerations residues , 2 - 0 - sulfation of iduronic and glucuronic acid , as 
Heparan sulfates ( HSs ) are highly sulfated polysaccha well as 6 - O - sulfation and 3 - 0 - sulfation of glucosamine . 
rides present on the surface of mammalian cells and in the Several enzymes that are responsible for the biosynthesis of 
extracellular matrix in large quantities . HS is a highly HS have been cloned and characterized ( Esko , J . D . , and 
charged polysaccharide comprising 14 - linked glu - 5 Lindahl , U . ( 2001 ) J . Clin . Invest . 108 : 169 - 173 ) . 
cosamine and glucuronic / iduronic acid units that contain The expression levels of various HS biosynthetic enzyme 
both N - and O - sulfo groups . Heparin , a specialized form of isoforms contribute to the synthesis of specific saccharide 
HS , is a commonly used anticoagulant drug . Thus , “ heparan sequences in specific tissues . HS N - deacetylase / N - sul 
sulfate ” , as used herein , includes heparin . fotransferase , 3 - O - sulfotransferase , and 6 - O - sulfotrans 
Heparin is a polysaccharide that comprises a disaccha - 10 ferase are present in multiple isoforms . Each isoform is 
ride - repeating unit of either iduronic acid ( Ido A ) or glu - believed to recognize a saccharide sequence around the 
curonic acid ( GICA ) and glucosamine residues , each capable modification site in order to generate a specific sulfated 
of carrying sulfo groups . The locations of the sulfo groups , saccharide sequence ( Liu , J . , et al . , ( 1999 ) J . Biol . Chem . 
Ido A and GlcA dictate the anticoagulant activity of heparin . 274 : 5185 - 5192 ; Aikawa , J . - I . , et al . , ( 2001 ) J . Biol . Chem . 
In vivo , heparin is synthesized by a series of heparan sulfate 15 276 : 5876 - 5882 ; Habuchi , H . , et al . , ( 2000 ) J . Biol . Chem . 
( HS ) biosynthetic enzymes ( FIG . 2 ) . HS polymerase cata - 275 : 2859 - 2868 ) . For instance , HS D - glucosaminyl 3 - 0 
lyzes the formation of the polysaccharide backbone , a sulfotransferase ( 3 - OST ) isoforms generate 3 - 0 - sulfated 
repeating disaccharide of GlcA and N - acetylated glu - glucosamine residues that are linked to different sulfated 
cosamine ( GlcNAc ) . This backbone is then modified by iduronic acid residues . 3 - OST isoform 1 ( 3 - OST - 1 ) transfers 
N - deacetylase / N - sulfotransferase ( NDST ) , Cz - epimerase 20 sulfate to the 3 - OH position of an N - sulfated glucosamine 
( Cz - epi ) , 2 - 0 - sulfotransferase ( 2 - OST ) , 6 - 0 - sulfotrans - residue that is linked to a glucuronic acid residue at the 
ferase ( 6 - OST ) , and 3 - 0 - sulfotransferase ( 3 - OST ) . The nonreducing end ( GIUA - GlcNS + 6S ) . However , 3 - OST iso 
availability of recombinant forms of HS biosynthetic form 3 ( 3 - OST - 3 ) transfers sulfate to the 3 - OH position of 
enzymes offers a new strategy to prepare heparin polysac an N - unsubstituted glucosamine residue that is linked to a 
charides and oligosaccharides . Traditionally , heparin oli - 25 2 - 0 - sulfated iduronic acid at the nonreducing end 
gosaccharides have been chemically synthesized through ( IDOUA2S - GlcNH2 + 6S ) ( Liu , J . , et al . , ( 1999 ) J . Biol . Chem . 
lengthy routes . Although several synthetic strategies have 274 : 38155 - 38162 ) . The difference in the substrate specific 
been reported , the chemical synthesis of heparin oligosac - ity of 3 - OSTs results in distinct biological functions . For 
charides is extremely challenging , especially for oligosac - example , the HS modified by 3 - OST - 1 binds to antithrombin 
charides larger than octasaccharides having a high content of 30 ( AT ) and possesses anticoagulant activity ( Liu , J . , et al . , 
sulfo groups . Chemoenzymatic methods have significantly ( 1996 ) J . Biol . Chem . 271 : 27072 - 27082 ) . However , the HS 
simplified the synthesis , offering a practical approach to modified by 3 - OST - 3 ( 3 - OST - 3A and 3 - OST - 3B ) binds to 
prepare synthetic LMWHs . glycoprotein D ( gD ) of herpes simplex virus , type 1 , ( HSV 
Heparin compounds of the presently disclosed subject 1 ) thus mediating viral entry ( Shukla , D . , et al . , ( 1999 ) Cell 
matter can comprise a synthetically sulfated polysaccharide 35 99 : 13 - 22 ) . 
possessing one or more structural and / or functional proper Cell surface HS also assists HSV - 1 infection ( WuDunn , 
ties of heparan sulfates . Although exemplary embodiments D . , and Spear , P . G . ( 1989 ) J . Virol . 63 : 52 - 58 ) . One report 
of particular heparin compounds have been disclosed herein , ( Shukla , D . , et al . , ( 1999 ) Cell 99 : 13 - 22 ) suggests that a 
the presently disclosed subject matter is not intended to be specific 3 - O - sulfated HS is involved in assisting HSV - 1 
limited to the disclosed examples , but rather heparin com - 40 entry . The 3 - O - sulfated HS is generated by 3 - OST - 3 but not 
pounds include all comparable synthetically sulfated poly - by 3 - OST - 1 . In addition , the 3 - 0 - sulfated HS provides 
saccharides as would be apparent to one of ordinary skill . binding sites for HSV - 1 envelope glycoprotein D , which is 
Indeed , one of ordinary skill in the art , upon a review of the a key viral protein involved in the entry of HSV - 1 ( Shukla , 
instant disclosure , is capable of producing numerous heparin D . , et al . , ( 1999 ) Cell 99 : 13 - 22 ) . Because 3 - OST - 3 - modified 
compounds based upon the disclosed methods and com - 45 HS is rarely found in HS from natural sources , the study 
pounds . suggests that HSV - 1 recognizes a unique saccharide struc 
Heparins play roles in a variety of important biological ture . Indeed , the result from the structural characterization of 
processes , including assisting viral infection , regulating a gD - binding octasaccharide revealed that the octasaccha 
blood coagulation and embryonic development , suppressing ride possesses a specific saccharide sequence ( Liu , J . , et al . , 
tumor growth , and controlling the eating behavior of test 50 ( 2002 ) J . Biol . Chem . 277 : 33456 - 33467 ) . In addition , the 
subjects by interacting with specific regulatory proteins binding affinity of the 3 - 0 - sulfated HS for gD is about 2 uM 
( Liu , J . , and Thorp , S . C . ( 2002 ) Med . Res . Rev . 22 : 1 - 25 ; ( Shukla , D . , et al . , Cell 99 : 13 - 22 ) . This affinity is similar to 
Rosenberg , R . D . , et al . , ( 1997 ) J . Clin . Invest . 99 : 2062 that reported for the binding of gD to the protein receptors , 
2070 ; Bernfield , M . , et al . , ( 1999 ) Annu . Rev . Biochem . suggesting that HSV - 1 utilizes both protein and HS cell 
68 : 729 - 777 ; Alexander , C . M . , et al . , ( 2000 ) Nat . Genet . 55 surface receptors to infect target cells ( Willis , S . H . , et al . , 
25 : 329 - 332 ; Reizes , O . , et al . , ( 2001 ) Cell 106 : 105 - 116 ) . ( 1998 ) J . Virol . 72 : 5938 - 5947 ; Krummenacher , C . , et al . , 
The unique sulfated saccharide sequences can determine to ( 1999 ) J . Virol . 73 : 8127 - 8137 ) . It is believed that the inter 
which specific proteins heparins bind , thereby regulating action between gD and the 3 - O - sulfated protein entry recep 
biological processes . tors somehow triggers the fusion between the virus and the 
The biosynthesis of heparin occurs in the Golgi apparatus . 60 cell in the presence of other viral envelope proteins , includ 
It can initially be synthesized as a copolymer of glucuronic ing gB , GH , and gL ( Shukla , D . , and Spear , P . G . ( 2001 ) J . 
acid and N - acetylated glucosamine by D - glucuronyl and Clin . Invest . 108 : 503 - 510 ) . A study of the co - crystal struc 
N - acetyl - D - glucosaminyltransferase , followed by various ture of gD and herpes entry receptor HveA suggests that the 
modifications ( Lindahl , U . , et al . , ( 1998 ) J . Biol . Chem . binding of HveA to gD induces conformational changes in 
273 : 24979 - 24982 ) . These modifications can include 65 gD ( Carfi , A . , et al . , ( 2001 ) Mol . Cell 8 : 169 - 179 ) . 
N - deacetylation and N - sulfation of glucosamine , C H S - regulated anticoagulation mechanisms have been 
epimerization of glucuronic acid to form iduronic acid studied extensively . It is now known that HS , including 
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heparin , interact with AT , a serine protease inhibitor , to adjusted accordingly as would be understood by one of 
inhibit the activities of thrombin and factor Xa in the blood ordinary skill in the art . Any suitable approach to determine 
coagulation cascade ( Rosenberg , R . D . , et al . , ( 1997 ) J . Clin . anticoagulant activity can be employed as would be appre 
Invest . 99 : 2062 - 2070 ) . Anticoagulant - active HS ( HSact ) and ciated by one of ordinary skill in the art upon review of the 
heparin contain one or multiple AT - binding sites per poly - 5 instant disclosure . 
saccharide chain . This binding site contains a specific pen - In some embodiments , the disclosed heparin compounds 
tasaccharide sequence with a structure of - GlcNS ( or Ac ) 6S - can have an anticoagulant activity that is reversible in the 
GlcUA - GlcNS3S ( 6S ) - IDOUA2S - GlcNS6S - . The 3 - 0 presence of a reversing agent , such as for example 
sulfation of glucosamine for generating GlcNS3S ( + 65 ) protamine . In some embodiments , a heparin compound can 
residue , which is carried out by 3 - OST - 1 , plays a role in the 10 have an anticoagulant activity that is completely reversible , 
synthesis of HSact ( Liu , J . , et al . , ( 1996 ) J . Biol . Chem . substantially completely reversible , or at least partially 
271 : 27072 - 27082 ; Shworak , N . W . , et al . , ( 1997 ) J . Biol . reversible by protamine . In some embodiments , a heparin 
Chem . 272 : 28008 - 28019 ) . compound having anticoagulant activity that is reversible at 
IV . Heparin Compounds a rate of 50 % or more in the presence of 20 ug / ml or less of 
In accordance with some embodiments , heparin com - 15 protamine is partially reversible . In some embodiments , a 
pounds of the presently disclosed subject matter can have a heparin compound having anticoagulant activity that is 
strong binding affinity for AT . By way of non - limiting reversible at a rate of 50 % or more in the presence of 100 
example , the binding constant ( KJ ) of heparin compounds of ug / ml or less , 50 ug / ml or less , 30 ug / ml or less , 20 ug / ml 
the presently disclosed subject matter can range from about or less , 15 ug / ml or less , 10 ug / ml or less , 5 ug / ml or less , 
3 to about 100 nM . In some embodiments , the binding 20 or 1 ug / ml or less of protamine is partially reversible . In 
constant ( Kg ) of a heparin compound of the presently some embodiments , a heparin compound of the present 
disclosed subject matter can range from about 5 to about 40 disclosure is considered to have a reversible anticoagulant 
nM . Any suitable approach to determine binding affinity can activity if the anticoagulant activity of the heparin com 
be employed as would be appreciated by one of ordinary pound is reversible at a rate similar to that of unfractionated 
skill in the art upon review of the instant disclosure . 25 heparin , as would be appreciated by one of ordinary skill in 
In some embodiments , heparin compounds disclosed the art upon a review of the instant disclosure . 
herein can have a molecular weight ranging from about An important clinical benefit of the disclosed heparin 
1 , 500 daltons ( Da ) to about 6 , 000 Da . In some embodi - compounds is their ability to be cleared from the circulation 
ments , the term low molecular weight ( LMW ) heparin , is through the liver , allowing these agents to be used in 
intended to refer to a heparin compound ranging in size from 30 renal - impaired patients . Unfractionated heparin ( UFH ) and 
3 , 500 to 6 , 000 Da and having from about 12 to 20 saccharide larger chained heparin compounds can bind to stabilin - 2 , a 
units , and in some embodiments having anticoagulant activ - scavenger receptor present on liver sinusoidal endothelial 
ity . In some embodiments , a LMW heparin of the presently cells that mediates their clearance . In some embodiments , 
disclosed subject matter can be about 3 , 500 Da , about 4 , 000 the disclosed heparin compounds displayed significant 
Da , about 4 , 500 Da , about 5 , 000 Da , about 5 , 500 Da , or 35 endocytosis mediated by Stabilin - 2 as measured in a cell 
about 6 , 000 Da . In some embodiments , a LMW heparin of based assay . 
the presently disclosed subject matter can have 12 , 14 , 16 , As shown by Pempe et al , 2012 , heparin compounds with 
18 or 20 saccharide units . In some embodiments , a LMW a 3 - 0 sulfation can be more efficiently taken up and cleared 
heparin of the presently disclosed subject matter can have by liver . See also Yu et al , 2014 . In accordance with some 
anticoagulant activity that is reversible in the presence of an 40 aspects of the presently disclosed subject matter , the sulfa 
antidote , such as for example protamine . tion pattern of the presently disclosed heparin compounds 
In some embodiments the anticoagulant activity can be can impact the clearance of such compounds through the 
measured by determining anti - Xa and anti - lla activities . In liver . Thus , in some embodiments , a synthetic , low - molecu 
some embodiments , the anti - Xa and anti - lla activities can be lar weight heparin compound susceptible to liver - mediated 
determined in the presence of antithrombin . Heparin com - 45 clearance from circulation comprises a 3 - 0 sulfation . In 
pounds with a strong binding affinity for AT and / or a high some aspects , heparin compounds disclosed herein that are 
anticoagulant activity can have high anti - Xa and anti - lla dodecamers or longer with a 3 - 0 sulfation can have such 
activities . In some embodiments , heparin compounds with enhanced liver clearance . In some embodiments , provided is 
high anticoagulant activity can have ICso values for anti - Xa a sulfation pattern , such as a 3 - 0 sulfation pattern , in a 
activity ranging from about 1 to about 20 nM . In some 50 synthetic , low - molecular weight heparin compound , such as 
embodiments , heparin compounds with high anticoagulant a dodecamer or larger synthetic oligosaccharide , which 
activity can have IC50 values for anti - Xa activity ranging matches the requirements for rapid liver clearance . 
from about 1 to about 10 nM . In some embodiments , heparin Thus , in some embodiments , heparin compounds of the 
compounds with high anticoagulant activity can have IC50 presently disclosed subject matter can be susceptible to 
values for anti - Xa activity ranging from about 1 to about 5 55 Stablin - 2 mediated endocytosis , wherein a heparin com 
nM . In some embodiments , heparin compounds with high pound that is endocytosed at a rate of 15 % or more is 
anticoagulant activity can have IC50 values for anti - Xa susceptible to Stablin - 2 mediated endocytosis . In some 
activity ranging from about 10 ngml - l to about 40 ngml - ? embodiments , a heparin compound that is endocytosed at a 
under the conditions disclosed herein . In some embodi - rate of 20 % , 25 % , 30 % , 35 % , 40 % , 45 % , 50 % , 75 % , 90 % 
ments , heparin compounds with high anticoagulant activity 60 or more is susceptible to Stablin - 2 mediated endocytosis . 
can have IC50 values for anti - Xa activity ranging from about Thus , provided in some aspects are synthetic , low - molecular 
15 ngml - ! to about 35 ngml - , under the conditions dis - weight heparin compounds susceptible to liver - mediated 
closed herein . As would be appreciated by one of ordinary clearance from circulation . In some embodiments , the hepa 
skill in the art , IC50 values are relative to the conditions r in compounds can be susceptible to Stablin - 2 mediated 
under which the measurements are taken . As such , the IC50 65 endocytosis at a rate of 15 % or more . Due to these charac 
values expressed herein are relative to the conditions under teristics , in some aspects the disclosed heparin compounds 
which the measurements were taken and can therefore be can be suitable for administration to renal - impaired patients . 
15 
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In some aspects , such heparin compounds that are suscep - towards further C5 - epi modification . Repeating these steps 
tible to liver - mediated clearance from circulation comprises ( step a to d , FIG . 3 ) once or twice can afford 8 and 9 , 
a sulfation pattern , such as a 3 - 0 sulfation pattern , such at respectively . 
least one 3 - 0 sulfate , and in some aspects can be a In some embodiments , the products of the disclosed and 
dodecamer . 5 illustrated reactions can contain a pnp tag with a strong 
Five homogenous LMWHs ( Compounds 1 - 5 , FIGS . absorbance at 310 nm , facilitating purity analysis by high 
1A - 1E , respectively ) , ranging from hexa - to dodeca - saccha performance liquid chromatography ( HPLC ) . Structures 
ride , can be synthesized . The structures of Compounds 1 - 4 were determined by electrospray ionization mass spectrom 
etry ( ESI - MS ) , one - dimensional ( 1D ) and two - dimensional differ at their reducing ends , containing a different number 
of - Ido A2S - GlcNS6S - repeating units . Dodecasaccharide 5 10 ( 2D ) nuclear magnetic resonance ( NMR ) analysis . Diethyl aminoethyl ( DEAE ) - HPLC analysis demonstrates that 5 is differs from 4 , as it has two 3 - O - sulfo groups ( FIGS . 1D and of high purity , MS affords an observed mass of 3562 . 8755 , 1E ) . The synthesis of Compound 1 can in some embodi very close to the calculated exact mass of 3562 . 9087 and ments be initiated from a commercially available monosac observed isotopic distribution for C20H121N _ 0115S17 
charide , 1 - 0 - ( para - nitrophenyl ) glucuronide ( GlcA - pnp ) 15 matches the simulated distribution . 1H - NMR spectrum of 5 
( FIG . 2 ) . Elongation of GlcA - pnp to a hexasaccharide can be depicts the presence of 12 anomeric protons . Additional 1 - D 
accomplished using two bacterial glycosyltransferases : KfA NMR and 2 - D NMR analysis confirmed the correct glyco 
( N - acetylglucosaminyl transferase from E . coli K5 strain ) sidic linkages and led to the spectral assignment of 5 . 
and heparosan synthase 2 ( pmHS2 ) from Pasteurella mul - MS - assisted sequence analysis pinpointed the residues car 
tocida . The subsequent N - sulfation , O - sulfations and 20 rying 3 - O - sulfo groups . 
epimerization steps permitted to prepare Compound 1 . The An important clinical benefit of UFH and some LMWH 
approach can also afford for the synthesis of hexasaccharide chains is their ability to be cleared from the circulation 
6 , an intermediate for subsequent syntheses . through the liver , allowing these agents to be used in 
The synthesis of Compounds 2 , 3 , and 4 can be initiated renal - impaired patients . Synthetic LMWHs were examined 
from hexasaccharide 6 through intermediates 7 , 8 and 9 , 25 to determine if they displayed similar clearance profiles . 
respectively ( FIG . 3 ) . These intermediates contain multiple UFH and larger chains in LMWH are known to bind to 
- IdoA2S - GlcNS6S - repeating units , posing a synthetic chal stabilin - 2 , a scavenger receptor present on liver sinusoidal 
lenge due to the substrate specificity of C5 - epi25 . endothelial cells that mediates their clearance . Like UFH 
FIG . 3 is a schematic illustration of the synthesis of and LOVENOX® , Compounds 3 , 4 and 5 displayed sig 
synthetic LMWHs as disclosed herein , and particularly the the 30 nificant endocytosis mediated by Stabilin - 2 as measured in a cell - based assay , while Compounds 1 and 2 displayed very synthesis of Compounds 2 to 5 . The synthesis can be low internalization ( FIG . 5 ) . Using a mouse model , the initiated from a hexasaccharide 6 . The hexasaccharide can retention of synthesized homogeneous LMWHs in the liver be converted to an octasaccharide ( 7 ) , decasaccharide ( 8 ) was compared with that of UFH and LOVENOX® ( FIG . 
and dodecasaccharide ( 9 ) to synthesize Compounds 2 , 3 , and 10 35 4A ) . Larger Compounds ( Compounds 3 , 4 and 5 ) were 4 , respectively . The conversion of Compounds 4 to 5 can be retained in the liver , while smaller size Compounds ( Com 
achieved by 3 - OST - 5 modification . pounds 1 and 2 ) showed very low level of retention in the The synthesis of intermediates , including Compounds 7 , liver ( FIG . 5 ) . 
8 and 9 , can in some aspects follow this scheme to avoid The anticoagulant activity of synthetic LMWHs was also 
yielding mixtures of products . When mixtures are formed , 40 determined . All compounds ( 1 - 5 ) displayed strong anti 
the synthetic efficiency will decrease dramatically . Because thrombin ( AT ) - binding affinity ( K , 5 - 30 nM ) ( Table 1 ) . 
many steps involved in the synthesis , only symbols are Results of anti - Xa activity assays showed lower IC50 values 
presented to represent the synthesis . The chemical structures for Compounds 1 - 5 than UFH and LOVENOX® , confirm 
of Compounds 1 - 9 are shown in FIGS . 1A - 11 , respectively . ing their potent anti - Xa activity ( FIG . 6 and Table 1 ) . Unlike 
A carefully designed sequence of enzymatic steps can be 45 UFH and LOVENOX® , synthetic LMWHs have no detect 
employed for high purity and yields . The conversion of able anti - lla activity , and thus , these compounds are Xa 
GlcA to IdoA2S involves two steps : the Cz - epi catalyzed specific inhibitors . The European Medicines Agency ( EMA ) 
epimerization of a GlcA to an IdoA ; and 2 - OST transferred recently approved a “ second - generation ” LMWH , Bemi 
a sulfo group to the Ido A residue . Co - epi catalyzes both the parin . Bemiparin has significantly lower anti - lla activity 
forward and reverse reactions , leading to the incomplete 50 than other LMWH drugs , but has very similar clinical utility , 
conversion of GlcA to IdoA2S26 and a complex mixture of suggesting that the anti - lla activity of LMWHs is less 
products27 . The placement of a pentasaccharide domain , critical . 
GlcN - trifluoroacetyl ( TFA ) - GlcA - GlcNS - GICA - GINS - , Next , the reversibility of the anticoagulant activity by 
into the substrate , directs Cz - epi to irreversibly react only protamine was determined . The in vitro protamine revers 
with one GlcA residue ( shown in bold ) and avoids incom - 55 ibility of five synthetic LMWHs ( FIG . 4B ) was compared . 
plete conversion . Unlike Compounds 1 , 2 , and 3 , Compound 4 was partially 
The conversion of Compound 6 to 7 , involving the reversed by protamine . Moreover , Compound 5 showed the 
compound of the pentasaccharide domain recognized by same protamine reversibility as UFH and greater reversibil 
C5 - epi , can be completed in four steps . The GlcNTFA ity than LOVENOX® ( FIG . 4B ) . Using an ex vivo mouse 
residue ( Residue F ) of hexasaccharide 6 can first be con - 60 model , it was confirmed that Compound 5 has similar 
verted to a GlcNS residue ( Step a , FIG . 3 ) . The hexasac - sensitivity to protamine neutralization as UFH ; as expected 
charide can then elongated to an octasaccharide in two only partial protamine neutralization was observed for 
enzymatic steps ( step b and c , FIG . 3 ) , to obtain the desired LOVENOX® ( FIG . 4C ) . Finally , using a mouse tail bleed 
pentasaccharide domain , as depicted in the dashed box ( FIG . ing model , it was demonstrated that protamine shortened the 
3 ) . The conversion of GlcA ( Residue E ) to IdoA2S to yield 65 primary bleeding time and reduced the blood loss that was 
7 can then achieved by Co - epi and 2 - OST ( step d , FIG . 3 ) . induced by Compound 5 ( FIG . 4D ) , confirming the sensi 
The formation of Ido A2S residue can remove its reactivity tivity of Compound 5 to protamine neutralization in vivo . 
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Summarily , FIGS . 4A - 4D illustrate that Compounds 3 , 4 or predetermined length , performing an epimerization reac 
and 5 are internalized in mice liver , and that the anti - Xa tion , and performing one or more sulfation reactions , 
activity of Compound 5 can be reversed by protamine in an whereby a heparin compound is synthesized . Alternatively , 
in vitro experiment , while the anti - Xa activity of other in some embodiments , the presently disclosed subject matter 
compounds , including enoxaparin ( brand name 5 provides a method of synthesizing a heparin compound , 
LOVENOX ) , is not reversible by protamine . UFH and comprising providing a monosaccharide or disaccharide 
Compound 5 have similar sensitivity to protamine neutral - substrate , elongating the monosaccharide or disaccharide substrate , elongating the monosaccharide or disaccharide 
ization . The anti - Xa activity of Compound 5 is reversible in substrate to a tetrasaccharide , elongating the tetrasaccharide to a hexasaccharide , wherein the hexasaccharide comprises an ex vivo experiment . Enoxaparin is only partially revers 
ible , but UFH is fully reversible . And , the anti - Xa activity of 10 a N - sulfotransferase substrate residue , converting the N - sul fotransferase substrate residue on the hexasaccharide to a Compound 5 can be reversed in an in vivo experiment . N - sulfo glucosamine ( GlcNS ) residue performing an Heparin and LMWHs are critical for the practice of epimerization reaction , and performing one or more sulfa 
modern medicine yet their production still depends on a long tion reactions selected from the group consisting of a 
supply chain , which is vulnerable to contamination and 2 - 0 - sulfation reaction , a 6 - 0 - sulfation reaction , a 3 - 0 
adulteration . After the heparin contamination crisis , the US sulfation reaction , and combinations thereof . These steps FDA and EMA have implemented a series of new can be repeated to form a octasaccharide , decasaccharide 
approaches to monitor the purity of heparin drugs . Although and / or dodecasaccharide to thereby synthesize a heparin 
these efforts have stopped the influx of contaminated heparin compound as disclose herein . 
into the market , a long term solution to secure the safety of 20 In some embodiments , the elongation step can comprise 
the heparin supply chain should be to manufacture synthetic employing a glycosyl transferase . By way of example and 
heparin under highly regulated processes , eliminating the not limitation , the glycosyl transferase can be N - acetyl 
needs for animal - sourced heparin . Chemoenzymatic synthe - glucosaminyl transferase of E . coli K5 ( KIA ) or heparosan 
sis offers an approach for this goal . The entire synthesis of synthase - 2 ( pmHS2 ) from Pasteurella multocida . In some 
homogenous LMWHs requires about 20 synthetic steps and 25 embodiments , the elongation step can comprise employing 
is potentially amenable to large - scale manufacturing . We one or more monosaccharides , which can comprise , for 
also demonstrate that the synthetic LMWHs have added example , glucuronic acid ( GICUA ) , N - acetylated glu 
pharmacological / clinical benefits . The chemoenzymatic cosamine ( GlcNAc ) , and N - trifluoroacetyl glucosamine ( Gl 
synthesis of LMWHs provides avenues for the next genera CNTFA ) . 
tion of heparin therapeutics . 30 In some embodiments , the step of converting the N - sul 
fotransferase substrate residue on the hexasaccharide or 
TABLE 1 heptasaccharide to a N - sulfo glucosamine ( GlcNS ) residue 
can comprise employing N - sulfotransferase ( NST ) and Summary of the synthesized LMWHs 3 ' - phosphoadenosine 5 ' - phosphosulfate ( PAPS ) . 
Amount Purity Affinity to Anti - FXa activity 35 To elaborate further , in some embodiments the epimeriza 
Compound ( mg ) ( % ) antithrombin ( K2 ) 2 ( IC50 , ngml - 1 ) 3 tion reaction can comprise employing Cs - epimerase ( C5 
epi ) , the 2 - 0 - sulfation reaction can comprise employing 5 299 7 + 2 nM 
> 99 8 + 3 nM 2 - 0 - sulfotransferase ( 2 - OST ) , the 6 - O - sulfation reaction 
6 299 5 + 1 nM can comprise employing 6 - O - sulfotransferase ( 6 - OST ) , and 
70 299 30 + 7 nM 40 the 3 - O - sulfation reaction can comprise employing 3 - 0 
sulfotransferase ( 3 - OST ) . 461 > 99 % 
344 > 95 % In some embodiments , the elongation steps can comprise 
263 99 % using a glycosyl transferase . In some aspects , the glycosyl 
183 99 % transferase can be N - acetyl glucosaminyl transferase of E . 
45 coli K5 ( KfiA ) . The purity was determined by DEAE - HPLC analysis . 
The Ky values are the average of two or three determinations . The Ky value for In some embodiments , a sequence of enzymatic steps are 
fondaparinux was previously reported to be 5 . 9 + 1 . 5 nM ( Xu , Y . et al . Science 334 , provided for synthesizing a dodecasaccharide as disclosed 498 - 501 , 2011 ) . 
PIC50 represents half maximal inhibitory concentration to inhibit the activity of factor FXa . herein in a highly efficient manner . In some embodiments , The IC50 value for fondaparinux was previously reported to be 4 . 5 ngml - Xu , Y . et al . 
Science 334 , 498 - 501 , 2011 ) . The lower IC50 value observed for fondaparinux is ascribed heparin compound synthesis can be initiated from hexasac 
to the different protocols used in the two experiments . 50 charide and continue through several intermediates until the " Compound 6 - 9 have no binding to antithrombin and do not inhibit FXa activity . final heparin compound . These intermediates contain mul 
V . Chemoenzymatic Synthesis of Ultra - Low Molecular tiple — IdoA2S - GlcNS6S - repeating units , posing a synthetic 
Weight Heparins challenge due to the substrate specificity of C5 - epi . A 
In some embodiments the presently disclosed subject designed sequence of enzymatic steps can be employed for 
matter provides enzymatic approaches to heparin com - 55 high purity and yields . Particularly , the conversion of GICA 
pounds , including structurally homogeneous low molecular to IdoA2S involves two steps : the Cz - epi catalyzed 
weight heparin compounds . The heparin compounds dis - epimerization of a GlcA to an IdoA ; and 2 - OST transferred 
closed herein can be synthesized from a monosaccharide a sulfo group to the Ido A residue . C - epi catalyzes both the 
building block using an enzymatic approach as disclosed forward and reverse reactions , leading to the incomplete 
herein . 60 conversion of GlcA to IdoA2S26 and a complex mixture of 
In some embodiments , the synthesis of heparin com - products . Such reactions can produce substantial amounts of 
pounds according to the presently disclosed subject matter b yproducts thereby rendering the process highly inefficient . 
can include backbone elongation and saccharide modifica - The placement of a pentasaccharide domain , GlcN - trifluo 
tion . In some embodiments , the presently disclosed subject roacetyl ( TFA ) - GlcA - GlcNS - GICA - GINS - , into the sub 
matter provides a method of synthesizing a heparin com - 65 strate , directs Cz - epi to irreversibly react only with one GICA 
pound , comprising providing a saccharide substrate , elon - residue ( shown in bold ) and reduces or avoids incomplete 
gating the saccharide substrate to a saccharide of a desired conversion . 
???? 
17 299 28 + 16 nM 
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The conversion of GlcA to IdoA2S can be achieved by In some embodiments , the chemoenzymatic syntheses 
Cz - epi and 2 - OST . The formation of Ido A2S residues employ sulfotransferases , such as O - sulfotransferases 
between the elongation steps between Octasaccharide , ( OSTs ) , to sulfate polysaccharides . Sulfotransferases com 
decasaccharide , and dodecasaccharide removes its reactivity prise a family of enzymes that catalyze the transfer of a 
towards further Cs - epi modification . Repeating these steps 5 sulfonate or sulfuryl group ( SO3 ) from a sulfo donor com 
allows for the elongation up to a dodecasaccharide , and the pound , i . e . an SO3 - donor molecule , to an acceptor molecule . 
synthesis of low - molecular weight heparin compounds dis By way of non - limiting example , the sulfo donor compound 
closed herein , while maintaining high efficiency of synthe or SO3 - donor molecule can be the cofactor 3 ' - phosphoad enosine - 5 - phosphosulfate ( PAPS ) . Even though it is more sis . For example , using the synthetic process as disclosed 
herein can heparin compounds , e . g . a dodecasaccharide , as 10 accurate to call these sulfonation reactions , the term sulfa tion is still widely used . Therefore , the term " sulfation " as depicted herein at efficiency rates of 50 % , 60 % , 70 % , 80 % , used herein refers to a transfer of a sulfonate or sulfuryl 90 % or more . This is in contrast to alternative approaches group from one molecule to another . where a heparin compound is elongated to a desired length , Sulfotransferases mediate sulfation of different classes of 
e . g . a dodecasaccharide , and then sulfated , which can yield 15 which can yield 15 substrates such as carbohydrates , oligosaccharides , peptides , 
significantly lower efficiencies , e . g . 2 % to 5 % . proteins , flavonoids , and steroids for a variety of biological 
In some embodiments , a heparin Compound of the pres - functions including signaling and modulation of receptor 
ently disclosed subject matter can have an R group that is binding ( Bowman et al . , ( 1999 ) Chem . Biol . 6 , R9 - R22 ; and 
detectable , for example , has UV or visible light absorbance . Falany ( 1997 ) FASEB J . 11 , 1 - 2 ) . Many new sulfotrans 
Designing and synthesizing a heparin Compound that is 20 ferases have been identified and cloned ( Aikawa et al . , 
detectable , for example has an R group that absorbs UV or ( 1999 ) J . Biol . Chem . 274 , 2690 ; Dooley ( 1998 ) Chemico 
visible light , can facilitate product purity detection and Biol . Interact . 109 , 29 ; Fukuta et al . ( 1998 ) Biochim . Bio 
isolation . Compounding a heparin compound with a UV or phys . Act . 1399 , 57 ; Habuchi et al . , ( 1998 ) J . Biol . Chem . 
visible light " tag ” can facilitate the monitoring of the 273 , 9208 ; Mazany et al . , ( 1998 ) Biochim . Biophys . Act . 
chemoenzymatic reactions and Compound synthesis . As 25 1407 , 92 ; Nastuk et al . ( 1998 ) J . Neuroscience 18 , 7167 ; 
would be appreciated by one of ordinary skill in the art , Ong et al . , ( 1998 ) J . Biol . Chem . 273 , 5190 ; Ouyang et al . , 
detecting a UV or visible light " tag " on a Compound during ( 1998 ) J . Biol . Chem . 273 , 24770 ; Saeki et al . ( 1998 ) J . 
or after synthesis can be achieved using any number of Biochem . 124 , 55 ; Uchimura et al . ( 1998 ) J . Biol . Chem . 
available spectrophotometric devices . In some embodi - 273 , 22577 ; and Yoshinari et al . , ( 1998 ) J . Biochem . 123 , 
ments , the " tag " can comprise a para - nitrophenyl . 30 740 ) . 
Alternatively , or in addition , in some embodiments the As used herein , the term “ O - sulfotransferase ( OST ) ” 
detectable R group can be a hydrophobic R group . As would includes polypeptides and nucleic acids encoding HS O - sul 
be appreciated by one of ordinary skill in the art , a hydro - fotransferases , such as for example “ 2 - OST ” ( e . g . , mouse 
phobic R group can allow the product to bind to a C18 2 - OST , GENBANK® Accession No . AAC40135 ; “ 3 - OST 
column , which can allow for the purification of the synthe - 35 1 ” ( e . g . , human 3 - OST - 1 , GENBANK® Accession No . 
sized heparins . NP _ 005105 ; “ 3 - OST - 3 ” ( e . g . , human 3 - OST - 3A , GEN 
In some embodiments , an R group , such as an R group BANK® Accession No . NP _ 006033 and human 3 - OST - 3B , 
that has UV or visible light absorbance , or a hydrophobic R GENBANK® Accession No . NP _ 006032 ; and “ 6 - OST " 
group , can be removable when the synthesis of the heparin ( e . g . , mouse 6 - OST - 1 , GENBANK® Accession No . 
is completed . As would be appreciated by one of ordinary 40 NP _ 056633 , mouse 6 - OST - 2 , GENBANK® Accession No . 
skill in the art , removing the R group once its utility is BAA89247 , and mouse 6 - OST - 3 , GENBANK® Accession 
achieved can facilitate the final processing of the heparin No . NP _ 056635 ) , which are HS 2 - O - sulfotransferase , HS 
Compound . For example , in some aspect it might be desir 3 - 0 - sulfotransferase isoform 1 , HS 3 - O - sulfotransferase 
able to remove the R group to avoid potential toxic func - isoform 3 , and HS 6 - 0 - sulfotransferase , respectively . In 
tional groups entering into a heparin drug compound 45 some embodiments , an OST can comprise 3 - OST - 5 . 
V . A . Enzymes Employed in Chemoenzymatic Synthesis of The term " OST ” includes invertebrate and vertebrate 
Heparin Compounds homologs of the O - sulfotransferases ( e . g . , mammalian ( such 
In some embodiments , the presently disclosed subject as human and mouse ) , insect , and avian homologs ) . As such , 
matter can utilize sulfotransferases , epimerases , glycosyl - although exemplary embodiments of particular OSTs have 
transferases , and / or heprosan synthases , among other 50 been disclosed herein , the presently disclosed subject matter 
enzymes as would be appreciated by one of ordinary skill in is not intended to be limited to the disclosed examples , but 
the art . These enzymes , and others that would be employed rather “ OST ” , including particular OSTs ( e . g . , 2 - OST , 
by one of ordinary skill in the art , are referred to herein as 3 - OST - 1 , 3 - OST - 3 , and 6 - OST ) , includes all comparable 
“ the enzymes ” , “ these enzymes ” , and / or “ enzymes ” . In OSTs known to the skilled artisan . 
some embodiments the chemoenzymatic syntheses can 55 In some embodiments the disclosed chemoenzymatic 
employ NST , Cz - epimerase ( Cz - epi ) , 2 - OST , 6 - OST - 1 , syntheses can employ Cz - epimerase ( Cz - epi ) . As such , 
6 - OST - 3 , 3 - OST - 1 , 3 - OST - 5 , N - acetyl glucosaminyl trans - although exemplary embodiments of particular epimerases 
ferase of E . coli K5 ( KfiA ) , and / or heparosan synthase - 2 have been disclosed herein , the presently disclosed subject 
( pmHS2 ) . In some embodiments these and other enzymes matter is not intended to be limited to the disclosed 
employed in the chemoenzymatic syntheses can be 60 examples , but rather “ epimerase ” , including Cz - epi , includes 
expressed in E . coli and purified by appropriate affinity all comparable epimerases known to the skilled artisan . 
chromatography as described previously ( Liu et al . , 2010 ) . Indeed , other epimerases , or compounds having epimerase 
In some embodiments , one or more of the converting activity , can be employed without departing from the scope 
reactions can employ a base compound or solution as would of the presently disclosed subject matter . 
be appreciated by one of ordinary skill in the art . Such bases 65 In some embodiments the disclosed chemoenzymatic 
can include for example lithium hydroxide or a mixture of syntheses can employ N - acetyl glucosaminyl transferase of 
triethylamine , CH2OH , and / or H2O . E . coli K5 ( KfiA ) . As such , although exemplary embodi 
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ments of particular glucosaminyl transferase have been tide ” , “ heparosan synthase gene product " , " heparosan 
disclosed herein , the presently disclosed subject matter is synthase protein ” , and “ heparosan synthase polypeptide ” 
not intended to be limited to the disclosed examples , but also include fusion or recombinant polypeptides and pro 
rather “ glucosaminyl transferase ” , including KfiA , includes teins comprising sequences of the enzyme protein . Methods 
all comparable glucosaminyl transferases known to the 5 of preparing such proteins are known in the art . 
skilled artisan . Indeed , other glucosaminyl transferases , or The terms " OST gene product " , " OST protein ” , “ OST 
compounds having similar transferase activity , can be polypeptide ” , “ epimerase gene product ” , “ epimerase pro 
employed without departing from the scope of the presently tein ” , “ epimerase polypeptide ” , “ glucosaminyl transferase 
disclosed subject matter . gene product ” , “ glucosaminyl transferase protein ” , “ glu 
In some embodiments the disclosed chemoenzymatic 10 cosaminyl transferase polypeptide ” , “ heparosan synthase 
syntheses can employ heparosan synthase - 2 ( pmHS2 ) . As gene product ” , “ heparosan synthase protein ” , and “ heparo 
such , although exemplary embodiments of particular hepa - san synthase polypeptide ” refer to any DNA sequence that is 
rosan synthases have been disclosed herein , the presently substantially identical to a polynucleotide sequence encod 
disclosed subject matter is not intended to be limited to the ing an enzyme isoform gene product , protein or polypeptide 
disclosed examples , but rather " heparosan synthase ” , 15 as defined above , and can also comprise any combination of 
including pmHS2 , includes all comparable heparosan syn - associated control sequences . The terms also refer to RNA , 
thases known to the skilled artisan . Indeed , other heparosan or antisense sequences , complementary to such DNA 
synthases , or compounds having similar synthase activity , sequences . As used herein , the term “ DNA segment ” refers 
can be employed without departing from the scope of the to a DNA molecule that has been isolated free of total 
presently disclosed subject matter . 20 genomic DNA of a particular species . Furthermore , a DNA 
The terms " OST gene product ” , “ OST protein ” , " OST segment encoding a polypeptide of one of these enzymes 
polypeptide " , " epimerase gene product " , " epimerase pro - refers to a DNA segment that contains coding sequences for 
tein ” , “ epimerase polypeptide ” , “ glucosaminyl transferase one of these enzymes , yet is isolated away from , or purified 
gene product ” , “ glucosaminyl transferase protein " , " glu - free from , total genomic DNA of a source species , such as 
cosaminyl transferase polypeptide " , " heparosan synthase 25 for example Homo sapiens . Included within the term “ DNA 
gene product ” , “ heparosan synthase protein " , and " heparo - segment " are DNA segments and smaller fragments of such 
san synthase polypeptide ” refer to peptides having amino segments , and also recombinant vectors , including , for 
acid sequences which are substantially identical to native example , plasmids , cosmids , phages , viruses , and the like . 
amino acid sequences from the organism of interest and The term " substantially identical " , when used to define 
which are biologically active in that they comprise all or a 30 either a gene product of one of these enzymes or amino acid 
part of the amino acid sequence of an O - sulfotransferase , sequence , or an enzyme gene or nucleic acid sequence , 
epimerase , glucosaminyl transferase , or heprosan synthase , means that a particular sequence varies from the sequence of 
or cross - react with antibodies raised against such enzymes , a natural enzyme by one or more deletions , substitutions , or 
or retain all or some of the biological activity of the native additions , the net effect of which is to retain at least some of 
amino acid sequence or protein of such enzymes . Such 35 biological activity of the natural gene , gene product , or 
biological activity can include immunogenicity . sequence . Such sequences include “ mutant ” sequences , or 
The terms “ OST gene product ” , “ OST protein ” , “ OST sequences in which the biological activity is altered to some 
polypeptide " , " epimerase gene product " , " epimerase pro - degree but retains at least some of the original biological 
tein ” , “ epimerase polypeptide ” , “ glucosaminyl transferase activity . 
gene product ” , “ glucosaminyl transferase protein ” , “ glu - 40 Alternatively , DNA analog sequences are “ substantially 
cosaminyl transferase polypeptide ” , “ heparosan synthase identical ” to specific DNA sequences disclosed herein if : ( a ) 
gene product ” , “ heparosan synthase protein ” , and “ heparo - the DNA analog sequence is derived from coding regions of 
san synthase polypeptide ” also include analogs of the the natural enzyme gene ; or ( b ) the DNA analog sequence is 
enzymes . By “ analog ” is intended that a DNA or peptide capable of hybridization of DNA sequences of ( a ) under 
sequence can contain alterations relative to the sequences 45 stringent conditions and which encode biologically active 
disclosed herein , yet retain all or some of the biological enzyme gene products ; or ( c ) the DNA sequences are 
activity of those sequences . Analogs can be derived from degenerate as a result of alternative genetic code to the DNA 
genomic nucleotide sequences as are disclosed herein or analog sequences defined in ( a ) and / or ( b ) . Substantially 
from other organisms , or can be created synthetically . Those identical analog proteins will be equal to or greater than 
skilled in the art will appreciate that other analogs , as yet 50 about 60 % , 70 % , 80 % , 90 % , 95 % , 96 % , 97 % , 98 % , or 99 % 
undisclosed or undiscovered , can be used to design and / or identical to the corresponding sequence of the native pro 
Compound analogs of these enzymes . There is no need for tein . Sequences having lesser degrees of identity but com 
a " OST gene product ” , “ OST protein ” , “ OST polypeptide ” , parable biological activity are considered to be equivalents . 
“ epimerase gene product ” , “ epimerase protein ” , “ epimerase In determining nucleic acid sequences , all subject nucleic 
polypeptide ” , “ glucosaminyl transferase gene product " , 55 acid sequences capable of encoding substantially similar 
" glucosaminyl transferase protein ” , “ glucosaminyl trans - amino acid sequences are considered to be substantially 
ferase polypeptide ” , “ heparosan synthase gene product " , similar to a reference nucleic acid sequence , regardless of 
“ heparosan synthase protein ” , and “ heparosan synthase differences in codon sequences or substitution of equivalent 
polypeptide ” to comprise all or substantially all of the amino amino acids to create biologically functional equivalents . 
acid sequence of a native enzyme gene product . Shorter or 60 Sequence identity or percent similarity of a DNA or 
longer sequences are anticipated to be of use in the presently peptide sequence can be determined , for example , by com 
disclosed subject matter , shorter sequences are herein paring sequence information using the GAP computer pro 
referred to as “ segments . ” Thus , the terms “ OST gene gram , available from the University of Wisconsin Geneticist 
product ” , “ OST protein ” , “ OST polypeptide ” , “ epimerase Computer Group . The GAP program utilizes the alignment 
gene product " , " epimerase protein " , " epimerase polypep - 65 method of Needleman et al . ( 1970 ) J Mol Biol 48 : 443 , as 
tide ” , “ glucosaminyl transferase gene product ” , “ glucosami - revised by Smith et al . ( 1981 ) Adv Appl Math 2 : 482 . Briefly , 
nyl transferase protein ” , “ glucosaminyl transferase polypep - the GAP program defines similarity as the number of aligned 
23 
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Pro A 
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symbols ( i . e . , nucleotides or amino acids ) that are similar , TABLE 2 - continued divided by the total number of symbols in the shorter of the 
two sequences . The preferred parameters for the GAP pro Functionally Equivalent Codons 
gram are the default parameters , which do not impose a Amino Acids 
penalty for end gaps . See Schwartz et al . ( 1979 ) Nuc Acids 5 
Res 6 ( 2 ) : 745 - 755 ; Gribskov et al . ( 1986 ) Nuc Acids Res Lysine Lys K AAA AAG 
14 ( 1 ) : 327 - 334 . Leucine Leu L ?UA UUG CUA CUC CUG CUU 
In certain embodiments , the present subject matter con 
Met Methionine cerns the use of the enzyme genes and gene products that 
include within their respective sequences a sequence that is Asparagine Asn 
essentially that of an enzyme gene , or the corresponding 
protein . For example , the term “ a sequence essentially as Proline CCA CCC CCG CCU 
that of an OST gene ” , means that the sequence is substan Glutamine CAA CAG 
tially identical or substantially similar to a portion of an OST 15 
gene and contains a minority of bases or amino acids Arginine Arg R AGA AGG CGA CGC CGG CGU 
( whether DNA or protein ) which are not identical to those of Ser S ACG AGU UCA UCC UCG UCU 
an OST protein or an OST gene , or which are not a 
biologically functional equivalent . The terms “ a sequence Threonine Thr ? ACA ACC ACG ACU 
essentially as that of an epimerase gene ” , “ a sequence 20 van Val v GUA G?C GUG GUU essentially as that of a glycosyl transferase gene ” , and “ a 
sequence essentially as that of a heparosan synthase gene ” Tryptophan Trp W UGG 
have similar meanings . The term “ biologically functional Tyrosine Tyr Y VAC UAU equivalent ” is well understood in the art and is further 
defined in detail herein . Nucleotide sequences are “ essen - 25 
tially the same ” where they have between about 75 % and It will also be understood by those of skill in the art that 
about 85 % or more preferably , between about 86 % and amino acid and nucleic acid sequences can include addi 
about 90 % , or more preferably greater than 90 % , or more tional residues , such as additional N - or C - terminal amino 
preferably between about 91 % and about 95 % , or even more acids or 5 ' or 3 ' nucleic acid sequences , and yet still be 
preferably , between about 96 % and about 99 % ; of nucleic 30 encompassed by the enzymes disclosed herein , so long as 
acid residues which are identical to the nucleotide sequence the sequence retains biological protein activity where pro 
of the enzyme gene . Similarly , peptide sequences which tein expression is concerned . The addition of terminal 
have about 60 % , 70 % , 80 % , or 90 % , or preferably from sequences particularly applies to nucleic acid sequences 
90 - 95 % , or more preferably greater than 96 % , or more which can , for example , include various non - coding 
preferably 95 - 98 % , or most preferably 96 % , 97 % , 98 % , or 35 sequences flanking either of the 5 ' or 3 ' portions of the 
99 % amino acids which are identical or functionally equiva - coding region or can include various internal sequences , i . e . , 
lent or biologically functionally equivalent to the amino introns , which are known to occur within genes . 
acids of the enzyme polypeptide will be sequences which are The present subject matter also encompasses the use of 
" essentially the same ” . nucleotide segments that are complementary to the 
Gene products and encoding nucleic acid sequences for 40 sequences of the present subject matter , in one embodiment , 
the enzymes employed in the disclosed methods , which have segments that are fully complementary , i . e . complementary 
functionally equivalent codons , are also covered by the for their entire length . Nucleic acid sequences that are 
presently disclosed subject matter . The term “ functionally “ complementary ” are those , which are base - paired accord 
equivalent codon ” is used herein to refer to codons that ing to the standard Watson - Crick complementarity rules . As 
encode the same amino acid , such as the ACG and AGU 45 used herein , the term " complementary sequences ” means 
codons for serine . Applicants contemplate substitution of nucleic acid sequences which are substantially complemen 
functionally equivalent codons of Table 1 into sequences of tary , as can be assessed by the same nucleotide comparison 
the enzymes disclosed herein as equivalents . set forth above , or is defined as being capable of hybridizing 
to the nucleic acid segment in question under relatively 
TABLE 2 50 stringent conditions such as those described herein . A par 
ticular example of a complementary nucleic acid segment is 
Functionally Equivalent Codons an antisense oligonucleotide . 
Amino Acids Codons One technique in the art for assessing complementary 
sequences and / or isolating complementary nucleotide 
Alanine Ala A GCA GCC GCG GCU 55 sequences is hybridization . Nucleic acid hybridization will 
Cys Cysteine C be affected by such conditions as salt concentration , tem UGC UGU perature , or organic solvents , in addition to the base com 
Aspartic Acid Asp D GAC GAU position , length of the complementary strands , and the 
number of nucleotide base mismatches between the hybrid Glutamic acid Glu E GAA GAG 60 izing nucleic acids , as will be readily appreciated by those 
Phenylalanine Phe UUC UUU skilled in the art . Stringent temperature conditions will generally include temperatures in excess of about 30° C . , 
Glycine Gly G GGA GGC GGG GGU typically in excess of about 37° C . , and preferably in excess 
of about 45° C . Stringent salt conditions will ordinarily be Histidine His H CAC CAU 65 less than about 1 , 000 mM , typically less than about 500 mm , 
Isoleucine Ile I AUA AUC AUU and preferably less than about 200 mM . However , the 
combination of parameters is much more important than the 
N 
 
I 
H 
25 
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measure of any single parameter . See e . g . , Wethmur & gram is entitled CLUSTAL W and is described in Thompson 
Davidson ( 1968 ) J Mol Biol 31 : 349 - 370 . Determining et al . ( 1994 ) Nucleic Acids Res 22 ( 22 ) : 4673 - 4680 , among 
appropriate hybridization conditions to identify and / or iso other places . 
late sequences containing high levels of homology is well The term " gene ” is used for simplicity to refer to a 
known in the art . See e . g . , Sambrook et al . ( 2001 ) Molecular 5 functional protein , polypeptide or peptide encoding unit . As 
Cloning : A Laboratory Manual , Third Edition , Cold Spring will be understood by those in the art , this functional term 
Harbor Laboratory Press , Cold Spring Harbor , N . Y . includes both genomic sequences and cDNA sequences . 
For the purposes of specifying conditions of high strin - As noted above , modifications and changes can be made 
gency , preferred conditions are salt concentration of about in the structure of enzyme proteins and peptides described 
200 mM and temperature of about 45° C . One example of 10 herein and still constitute a molecule having like or other 
such stringent conditions is hybridization at 4xSSC , at 65° wise desirable characteristics . For example , certain amino 
C . , followed by a washing in 0 . 1xSSC at 65° C . for one hour . acids can be substituted for other amino acids in a protein 
Another exemplary stringent hybridization scheme uses structure without appreciable loss of interactive capacity 
50 % formamide , 4xSSC at 42° C . Another example of with , for example , structures in the nucleus of a cell . Since 
" stringent conditions ” refers to conditions of high strin - 15 it is the interactive capacity and nature of a protein that 
gency , for example 6xSSC , 0 . 2 % polyvinylpyrrolidone , defines that protein ' s biological functional activity , certain 
0 . 2 % Ficoll , 0 . 2 % bovine serum albumin , 0 . 1 % sodium amino acid sequence substitutions can be made in a protein 
dodecyl sulfate , 100 ug / ml salmon sperm DNA and 15 % sequence ( or the nucleic acid sequence encoding it ) to obtain 
formamide at 68° C . Nucleic acids having sequence simi - a protein with the same , enhanced , or antagonistic proper 
larity are detected by hybridization under low stringency 20 ties . Such properties can be achieved by interaction with the 
conditions , for example , at 50° C . and 10xSSC ( 0 . 9 M normal targets of the native protein , but this need not be the 
NaC1 / 0 . 09 M sodium citrate ) and remain bound when sub case , and the biological activity of the presently disclosed jected to washing at 55° C . in 1xSSC . Sequence identity can subject matter is not limited to a particular mechanism of 
be determined by hybridization under stringent conditions , action . It is thus contemplated in accordance with the present 
for example , at 50° C . or higher and 0 . 1xSSC ( 9 mM 25 subject matter that various changes can be made in the 
NaC1 /0 . 9 mM sodium citrate ) . sequence of the enzyme proteins and peptides or underlying 
Nucleic acids that are substantially identical to the pro nucleic acid sequence without appreciable loss of their 
vided enzymes , e . g . , allelic variants , genetically altered biological utility or activity . 
versions of the gene , etc . , bind to the disclosed OSTs under Biologically functional equivalent peptides , as used 
stringent hybridization conditions . By using probes , particu - 30 herein , are peptides in which certain , but not most or all , of 
larly labeled probes of DNA sequences , one can isolate the amino acids can be substituted . Thus , applicants con 
homologous or related genes . The source of homologous template substitution of codons that encode biologically 
genes can be any species , e . g . , primate species , particularly equivalent amino acids as described herein into the 
human ; rodents , such as rats and mice ; canines ; felines ; sequences of the disclosed enzymes , but which are not set 
bovines ; ovines ; equines ; insects ; yeasts ; nematodes ; etc . 35 forth herein in their entirety for convenience . 
Between mammalian species , e . g . , human , mouse and rat , Alternatively , functionally equivalent proteins or peptides 
homologs have substantial sequence similarity , i . e . at least can be created via the application of recombinant DNA 
75 % sequence identity between nucleotide sequences . technology , in which changes in the protein structure can be 
Sequence similarity is calculated based on a reference engineered , based on considerations of the properties of the 
sequence , which can be a subset of a larger sequence , such 40 amino acids being exchanged . Changes designed by man 
as a conserved motif , coding region , flanking region , etc . A can be introduced through the application of site - directed 
reference sequence will usually be at least about 18 nucleo - mutagenesis techniques , e . g . , to introduce improvements to 
tides long , more usually at least about 30 nucleotides long , the antigenicity of the protein or to test enzyme mutants in 
and can extend to the complete sequence that is being order to examine enzyme activity , or other activity at the 
compared . Algorithms for sequence analysis are known in 45 molecular level . 
the art , such as BLAST , described in Altschul et al . ( 1990 ) Amino acid substitutions , such as those which might be 
J Mol Biol 215 : 403 - 410 . The sequences provided herein are employed in modifying enzyme proteins and peptides 
essential for recognizing enzymes related and homologous described herein , are generally based on the relative simi 
proteins in database searches . larity of the amino acid side - chain substituents , for example , 
At a biological level , identity is just that , i . e . the same 50 their hydrophobicity , hydrophilicity , charge , size , and the 
amino acid at the same relative position in a given family like . An analysis of the size , shape and type of the amino 
member of a gene family . Homology and similarity are acid side - chain substituents reveals that arginine , lysine and 
generally viewed as broader terms . For example , biochemi - histidine are all positively charged residues ; that alanine , 
cally similar amino acids , for example leucine and isoleu - glycine and serine are all of similar size ; and that phenyl 
cine or glutamate / aspartate , can be present at the same 55 alanine , tryptophan and tyrosine all have a generally similar 
position — these are not identical per se , but are biochemi - shape . Therefore , based upon these considerations , arginine , 
cally “ similar ” . As disclosed herein , these are referred to as lysine and histidine ; alanine , glycine and serine ; and phe 
conservative differences or conservative substitutions . This nylalanine , tryptophan and tyrosine ; are defined herein as 
differs from a conservative mutation at the DNA level , biologically functional equivalents . Other biologically func 
which changes the nucleotide sequence without making a 60 tionally equivalent changes will be appreciated by those of 
change in the encoded amino acid , e . g . , TCC to TCA , both skill in the art . 
of which encode serine . When percentages are referred to In making biologically functional equivalent amino acid 
herein , it is meant to refer to percent identity . The percent substitutions , the hydropathic index of amino acids can be 
identities referenced herein can be generated by alignments considered . Each amino acid has been assigned a hydro 
with the program GENEWORKSTM ( Oxford Molecular , Inc . 65 pathic index on the basis of their hydrophobicity and charge 
of Campbell , Calif . , U . S . A . ) and / or the BLAST program at characteristics , these are : isoleucine ( + 4 . 5 ) ; valine ( + 4 . 2 ) ; 
the NCBI website . Another commonly used alignment pro - leucine ( + 3 . 8 ) ; phenylalanine ( + 2 . 8 ) ; cysteine ( + 2 . 5 ) ; 
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methionine ( + 1 . 9 ) ; alanine ( + 1 . 8 ) ; glycine ( - 0 . 4 ) ; threonine total length preferably being limited by the ease of prepa 
( - 0 . 7 ) ; serine ( - 0 . 8 ) ; tryptophan ( - 0 . 9 ) ; tyrosine ( - 1 . 3 ) ; ration and use in the intended recombinant DNA protocol . 
proline ( - 1 . 6 ) ; histidine ( - 3 . 2 ) ; glutamate ( - 3 . 5 ) ; glutamine For example , nucleic acid fragments can be prepared which 
( - 3 . 5 ) ; aspartate ( - 3 . 5 ) ; asparagine ( - 3 . 5 ) ; lysine ( - 3 . 9 ) ; include a short stretch complementary to a nucleic acid 
and arginine ( - 4 . 5 ) . 5 sequence set forth in any of the enzymes disclosed herein , 
The importance of the hydropathic amino acid index in such as about 10 nucleotides , and which are up to 10 , 000 or 
conferring interactive biological function on a protein is 5 , 000 base pairs in length , with segments of 3 , 000 being 
generally understood in the art ( Kyte et al . ( 1982 ) J Mol Biol preferred in certain cases . DNA segments with total lengths 
157 : 105 , incorporated herein by reference ) . It is known that of about 4 , 000 , 3 , 000 , 2 , 000 , 1 , 000 , 500 , 200 , 100 , and about 
certain amino acids can be substituted for other amino acids 10 50 base pairs in length are also contemplated to be useful . 
having a similar hydropathic index or score and still retain Recombinant vectors form further aspects of the present 
a similar biological activity . In making changes based upon subject matter . Particularly useful vectors are those in which 
the hydropathic index , the substitution of amino acids whose the coding portion of the DNA segment is positioned under 
hydropathic indices are within + 2 of the original value is the control of a promoter . The promoter can be that naturally 
preferred , those , which are within + l of the original value , 15 associated with an enzyme gene , as can be obtained by 
are particularly preferred , and those within + 0 . 5 of the isolating the 5 ' non - coding sequences located upstream of 
original value are even more particularly preferred . the coding segment or exon , for example , using recombinant It is also understood in the art that the substitution of like cloning and / or polymerase chain reaction ( PCR ) technology amino acids can be made effectively on the basis of hydro and / or other methods known in the art , in conjunction with philicity . U . S . Pat . No . 4 , 554 , 101 , incorporated herein by 
reference , states that the greatest local average hydrophilic 20 the compositions disclosed herein . In other embodiments , it is provided that certain advan ity of a protein , as governed by the hydrophilicity of its 
adjacent amino acids , correlates with its immunogenicity tages will be gained by positioning the coding DNA segment 
and antigenicity , i . e . with a biological property of the under the control of a recombinant , or heterologous , pro 
protein . It is understood that an amino acid can be substi moter . As used herein , a recombinant or heterologous pro tuted for another having a similar hydrophilicity value and 25 moter is a promoter that is not normally associated with an 
still obtain a biologically equivalent protein . enzyme gene in its natural environment . Such promoters can 
As detailed in U . S . Pat . No . 4 , 554 , 101 , the following include promoters isolated from bacterial , viral , eukaryotic , 
hydrophilicity values have been assigned to amino acid or mammalian cells . Naturally , it will be important to 
residues : arginine ( + 3 . 0 ) ; lysine ( + 3 . 0 ) ; aspartate ( + 3 . 0 : 1 ) ; employ a promoter that effectively directs the expression of 
glutamate ( + 3 . 0 - 1 ) ; serine ( + 0 . 3 ) ; asparagine ( + 0 . 2 ) ; gluta - 30 the DNA segment in the cell type chosen for expression . The 
mine ( + 0 . 2 ) ; glycine ( 0 ) ; threonine ( - 0 . 4 ) ; proline ( - 0 . 5 + 1 ) ; use of promoter and cell type combinations for protein 
alanine ( - 0 . 5 ) ; histidine ( - 0 . 5 ) ; cysteine ( - 1 . 0 ) ; methionine expression is generally known to those of skill in the art of ( - 1 . 3 ) ; valine ( - 1 . 5 ) ; leucine ( - 1 . 8 ) ; isoleucine ( - 1 . 8 ) ; tyro - molecular biology ( See , e . g . , Sambrook et al . ( 2001 ) 
sine ( - 2 . 3 ) ; phenylalanine ( - 2 . 5 ) ; tryptophan ( - 3 . 4 ) . Molecular Cloning : A Laboratory Manual , Third Edition , 
In making changes based upon similar hydrophilicity 35 Cold Spring Harbor Laboratory Press , Cold Spring Harbor , 
values , the substitution of amino acids whose hydrophilicity New York ) . The promoters employed can be constitutive or 
values are within + 2 of the original value is preferred , those , inducible and can be used under the appropriate conditions 
which are within + 1 of the original value , are particularly to direct high level expression of the introduced DNA 
preferred , and those within + 0 . 5 of the original value are segment , such as is advantageous in the large - scale produc 
even more particularly preferred . tion of recombinant proteins or peptides . 
While discussion has focused on functionally equivalent 40 In some embodiments of the method disclosed herein for 
polypeptides arising from amino acid changes , it will be sulfating polysaccharides , an enzyme of the presently dis 
appreciated that these changes can be effected by alteration closed subject matter ( e . g . sulfotransferases , epimerases , 
of the encoding DNA , taking into consideration also that the glycosyltransferases , and / or heprosan synthases ) can be 
genetic code is degenerate and that two or more codons can immobilized on a substrate . This provides an advantage in 
code for the same amino acid . 45 that the substrate to which the enzymes are attached can be 
Thus , it will also be understood that the presently dis - washed after a sulfation reaction to remove all components 
closed subject matter is not limited to the particular nucleic of the reaction except the bound enzymes . As such , the 
acid and amino acid sequences of the enzymes disclosed products of the reaction can be more easily separated from 
herein , including sulfotransferases , epimerases , glycosyl - the enzymes catalyzing the reaction and the enzymes can be 
transferases , and / or heprosan synthases . Recombinant vec - 50 recycled and utilized again in multiple sulfation reactions . In 
tors and isolated DNA segments can therefore variously some embodiments , the substrate is agarose . In particular 
include the enzyme polypeptide - encoding region itself , embodiments , the agarose substrate is an agarose bead and 
include coding regions bearing selected alterations or modi the enzymes are linked to the beads . 
fications in the basic coding region , or include larger poly . V . B . Reduction of Inhibitory Effects of PAP 
peptides which nevertheless comprise the enzyme polypep - 56 . The presently disclosed methods for synthesizing heparin 
tide - encoding regions or can encode biologically functional compounds can comprise the use of a PAPS regenerating 
equivalent proteins or peptides which have variant amino enzyme and a sulfo donor compound . The PAPS regenerat 
acid sequences . Biological activity of an enzyme can be ing enzyme catalyzes regeneration of the PAPS from the 
determined using techniques generally known in the art , for PAP utilizing the sulfo donor compound as a substrate . See , 
example as disclosed herein in the Examples . e . g . , U . S . Pat . No . 6 , 255 , 088 ; and Burkart et al . , ( 2000 ) J . 
The nucleic acid segments of the present subject matter , 60 Org . Chem . 65 , 5565 - 5574 , both of which are herein incor 
regardless of the length of the coding sequence itself , can be porated by reference in their entirety . Thus , the PAPS 
combined with other DNA sequences , such as promoters , regeneration system provides the dual advantages of reduc 
enhancers , polyadenylation signals , additional restriction ing the inhibitory effects of PAP accumulation on sulfotrans 
enzyme sites , multiple cloning sites , other coding segments , ferase activity while also constantly “ recharging ” the reac 
and the like , such that their overall length can vary consid - 65 tion mixture with the primary sulfo donor molecule , PAPS . 
erably . It is therefore contemplated that a nucleic acid In some embodiments , the PAPS regenerating enzyme is an 
fragment of almost any length can be employed , with the estrogen sulfotransferase . 
20 
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Thus , an aspect of the presently disclosed subject matter as 1 , 000 - fold . As such , in some embodiments of the pres 
is directed to a sulfo donor compound ( e . g . , PAPS ) regen - ently disclosed subject matter a method of sulfating a 
eration process coupled with sulfation of a polysaccharide polysaccharide is provided comprising providing a reaction 
substrate . In particular , the process can be of a type wherein mixture comprising therein adenosine 3 ' , 5 ' - diphosphate 
the sulfation of a polysaccharide substrate is catalyzed by a 5 ( PAP ) , a PAPS regenerating enzyme and a sulfo donor 
sulfotransferase , such as one or more OSTs , with a conver - compound ( other than PAPS , e . g . , PNPS ) and incubating the 
sion of 3 ' - phosphoadenosine - 5 ' - phosphosulfate ( PAPS ) to reaction mixture for a time period sufficient to catalyze the 
adenosine 3 ' , 5 ' - diphosphate ( PAP ) . The sulfation process production of 3 ' - phosphoadenosine 5 ' - phosphosulfate 
can be coupled with an enzymatic regeneration of the PAPS ( PAPS ) from the PAP by the PAPS regenerating enzyme 
from the PAP . The enzymatic regeneration can employ an 10 utilizing the sulfo donor compound as a substrate . The 
arylsulfotransferase as the catalyst and an aryl sulfate as a method further comprises incubating a polysaccharide sub 
substrate . In some embodiments , the enzymatic regeneration strate and at least one O - sulfotransferase ( OST ) enzyme 
can comprise a human or mouse estrogen sulfotransferase with the reaction mixture , wherein production of a sulfated 
( EST ) . As disclosed elsewhere herein , preferred carbohy - polysaccharide from the polysaccharide substrate is cata 
drate substrates can include GAGs , such as for example 15 lyzed by the OST enzyme with a conversion of the PAPS to 
heparan sulfates , including heparin . PAP and wherein the PAPS regenerating enzyme then cata 
Coupling the sulfotransferase catalyzed sulfation reaction lyzes regeneration of the PAPS from the PAP , again utilizing 
with a PAPS regeneration system can provide a further the sulfo donor compound as a substrate . An Appendix is 
advantage of generating PAPS utilized in the reaction included herewith and is intended to be part of the instant 
directly from PAP . That is , the reaction mixture can be 20 disclosure . 
formulated to combine PAP with a PAPS regenerating VI . Treatment Methods 
enzyme prior to or simultaneously with addition of a sul - In some embodiments , provided herein are methods of 
fotransferase to the reaction mixture . The PAPS regenerating treating a subject by administering one or more of the 
enzyme can then generate PAPS from the PAP for use by the heparin compounds disclosed herein . For example , in some 
sulfotransferase , thereby alleviating the need of supplying 25 aspects a method of treating a subject is provided , compris 
any of the more expensive and unstable PAPS to the reaction ing providing a subject to be treated and administering to the 
mixture . For example , coupling the PAPS regeneration sys - subject a heparin compound having anticoagulant activity . 
tem to use PNPS as a sulfo donor can potentially reduce the In some aspects , the heparin compound is one of the 
cost of the synthesis of sulfated polysaccharides by as much following : 
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- continued HO2SO 
0 HO?C IOOC HO2SO 
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HO3S 
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wherein R , is present or absent , and / or wherein when R , is 15 methods can comprise providing a subject in need of anti 
present it comprises a detectable tag , optionally para - nitro coagulant therapy , administering to the subject a heparin phenyl . In some aspects , the heparin compound used in such 
treatments is a heparin compound comprising a synthetic , compound having anticoagulant activity , monitoring the 
low - molecular weight heparin compound with reversible subject for heparin - induced thrombocytopenia , and admin 
anticoagulant activity , wherein the anticoagulant activity of istering to the subject an antidote to reverse the anticoagu 
the heparin compound is reversible by protamine , wherein 20 lant activity of the heparin compound if the subject suffers the anticoagulant activity is reversed by about 50 % or more in the presence of 1 ug / ml of protamine , as disclosed herein . from heparin - induced thrombocytopenia . In such methods 
In some embodiments , provided herein are methods of the heparin compound can comprise for example a heparin 
treating a subject in need of anticoagulant therapy . Such compound comprising a structure selected from : 
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- continued HO2SO 
HO?C HO3SO 
OH ?? HO3SO HN 
TO O HO250 – OH HOZS HN HOOC 
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HN 
To HOZS 
HO O Y OH 
HO3SO 
wherein R is present or absent , wherein when R2 is present 2010 ) . The resultant UDP - GlcNTFA was ready for the 
it comprises a detectable tag , optionally para - nitrophenyl . In 15 elongation reaction involved in using KfiA as described 
some aspects , the antidote to reverse the anticoagulant below . 
activity of the heparin compound is protamine . Synthesis of compound 6 . The conversion of a starting 
In some embodiments , a subject to be treated in any of the material GlcA - PNP to compound 6 involves seven steps , 
methods of treatment disclosed herein can be a subject including five elongation steps , one detrifluoroacetylation / 
suffering from venous thromboembolism . In some embodi - 20 N - sulfation step and one C5 - epimerization / 2 - 0 - sulfation 
ments , a subject to be treated can be a subject that is step . Elongation of GICA - PNP ( 100 mg , from Sigma - Al 
renal - impaired . In some embodiments , the subject is a drich ) to GlcA - GlcNTFA - GICA - GlcNTFA - GICA - PNP was 
human subject . completed in 4 steps using two bacterial glycosyl trans ferases , N - acetyl glucosaminyl transferase of E . coli K5 
EXAMPLES 25 ( KfiA ) and heparosan synthase - 2 ( pmHS2 ) from Pasteurella 
multocida . To introduce a GlcNTFA residue , GlcA - pnp ( 1 . 2 
mM ) was incubated with KiA ( 20 ugml - ) in a buffer The following Examples provide illustrative embodi 
ments . In light of the present disclosure and the general level containing Tris ( 25 mM , PH 7 . 5 ) , MnCl2 ( 15 mM ) and UDP - GlcNTFA ( 1 . 5 mM ) , at room temperature overnight . of skill in the art , those of skill will appreciate that the 
following Examples are intended to be exemplary only and 30 To introduce a GlcA residue , disaccharide substrate , GlcNTFA - GlcA - pnp ( 1 . 2 mM ) , was incubated with pmHS2 that numerous changes , modifications , and alterations can be ( 20 ugml - 1 ) in a buffer containing Tris ( 25 mM , pH 7 . 5 ) , employed without departing from the scope of the presently MnCl2 ( 15 mM ) and UDP - GICA ( 1 . 5 mM ) , at room tem 
claimed subject matter . perature overnight . The product after each elongation step 
35 was purified using a Cie column ( 0 . 75x20 cm ; Biotage ) , Materials and Methods for Examples 1 - 11 which was eluted with a linear gradient of 0 - 100 % acetoni 
trile in H , O and 0 . 1 % TFA in 60 min at a flow rate of 2 Expression of HS biosynthetic enzymes . A total of nine mlmin ? . The eluent was monitored by the absorbance at 
enzymes were used for the synthesis , including NST , C5 - epi , 310 nm , and the identity of the product was confirmed by 
2 - OST , 6 - OST - 1 , 6 - OST - 3 , 3 - OST - 1 , 3 - OST - 5 , KfA , and 40 ESI - MS . The addition of GlcNTFA and GlcA residues was 
pmHS2 . All enzymes were expressed in E . coli and purified repeated one more time to form a pentasaccharide backbone 
by appropriate affinity chromatography as described previ - for the subsequent N - detrifluoroacetylation / N - sulfation . 
ously ( Liu , R . et al . , J Biol Chem 285 , 34240 - 34249 , 2010 ; The pentasaccharide backbone was further subjected to 
Xu , D . , Moon , A . , Song , D . , Pedersen , L . C . & Liu , J . Nat detrifluoroacetylation , followed by N - sulfation with N - sul 
Chem Biol 4 , 200 - 202 , 2008 ) . 45 fotransferase ( NST ) . The pentasaccharide backbones ( 280 
Preparation of enzyme cofactors . A sulfo donor , 3 ' - phos - mg ) were dried and resuspended in 30 ml of 0 . 1 M LiOH on 
phoadenosine 5 ' - phosphosulfate ( PAPS ) , was prepared from ice for 2 h . The degree of completion of the detrifluoro 
ATP and sodium sulfate using adenosine phosphokinase and acetylation reaction was monitored by PAMN - HPLC analy 
ATP - sulfurylase ( Zhou , X . , Chandarajoti , K . , Pham , T . Q . , sis and ESI - MS . Upon the completion of detrifluoroacety 
Liu , R . & Liu , J . , Glycobiology 21 , 771 - 780 , 2011 ) . The 50 lation , the pH of the reaction mixture decreased to 7 . 0 and 
preparation of UDP - GlcNTFA was started from glu - incubated of MES 50 mM pH 7 . 0 , N - sulfotransferase 10 
cosamine ( Sigma - Aldrich ) , which was first converted to ugml - 1 and 0 . 5 mM PAPS in 780 ml at 37° C . overnight , 
GlcNTFA by reacting with S - ethyl trifluorothioacetate where the amount of PAPS was about 1 . 5 - times molar ( Sigma - Aldrich ) followed the protocol described previously amount of NH , groups in the pentasaccharide . N - sulfated 
( Liu , R . et al . , J Biol Chem 285 , 34240 - 34249 , 2010 ) . The 55 product was purified by Q column , and the purified product 
resultant GlcNTFA was converted to GlcNTFA - 1 - phosphate with the structure of GlcA - GlcNS - GICA - GlcNS - GICA - PNP 
using N - acetylhexosamine 1 - kinase ( Zhao , G . , Guan , W . , was dialyzed . 
Cai , L . & Wang , P . G . , Nat . Protoc . 5 , 636 - 646 , 2010 ) . The To GICA - GlcNS - GlcA - GlcNS - GlcA - pnp pentasaccha 
plasmid expressing N - acetylhexoamine 1 - kinase was a gen - ride , another GlcNTFA was introduced using KfiA following 
erous gift from Prof . Peng Wang ( Georgia State University ) , 60 the procedure as described above . The reaction was by 
and the expression of the enzyme was carried out in E . coli PAMN - HPLC to observe a shift in retention time of the peak 
as reported ( Zhao , G . , Guan , W . , Cai , L . & Wang , P . G . , Nat . with the absorbance at 310 nm . The reaction mixture was 
Protoc . 5 , 636 - 646 , 2010 ) . The UDP - GlcNTFA synthesis incubated with MES 50 mM ( pH 7 . 0 ) , Ca?i , 2 mM , 10 
was completed by transforming GlcNTFA - 1 - phosphate ugml - Cz - epi , 2 - OST 10 ugml - ? , 0 . 2 mM PAPS and 0 . 13 
using glucosamine - 1 - phosphate acetyltransferase / N - acetyl - 65 mM hexasaccharide substrate in 2 liter volume at 37° C . 
glucosamine - 1 - phosphate uridyltransferase ( GIMU ) as overnight . The reaction mixture was then purified by Q - Sep 
described ( Liu , R . et al . , J Biol Chem 285 , 34240 - 34249 , harose column to obtain Compound 6 . 
35 
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HPLC analysis . Both DEAE - HPLC and polyamine - based Example 3 
anion exchange ( PAMN ) - HPLC were used to analyze the 
purity of the products . The elution conditions for the HPLC Preparation of 35S - Labeled LMWHS 
analysis were described elsewhere ( Liu , R . et al . J Biol 
Chem 285 , 34240 - 34249 , 2010 ) . UFH ( from US Pharmacopea ) and LOVENOX® ( from 
local pharmacy ) were modified by N - sulfotransferase . Reac Example 1 tion consisted of MES 50 mM pH 7 . 0 , N - sulfotransferase 0 . 1 
mgml - 1 and 0 . 5 nmol [ 35S ] PAPS ( specificity activity of Synthesis of Compound 1 , 2 , 3 , 4 , and 5 10 . [ S ] PAPS was 2 . 2x104 cpm / pmol ) , UFH or LOVENOX® 
50 ug in total 500 ul at 37° C . overnight . The products were The conversion of compound 6 to 1 , compound 7 to 2 and purified by a DEAE - column . 35S - labeled LMWH Com 
compound 8 to 3 followed same reactions , including detri pounds 1 to 4 were prepared from the LMWH Compounds 
fluoroacetylation / N - sulfation , 6 - O - sulfation and 3 - 0 - sulfa intermediates without 3 - 0 - sulfo groups . Reaction consisted 
tion by 3 - OST - 1 enzyme . The conversion of compound 9 to 5 of MES 50 mM pH 7 . 0 , 10 mM MnCl2 , 5 mM MgCl2 , 
4 involved 2 steps , including 6 - O - sulfation and 3 - OST - 1 3 - OST - 1 0 . 1 mgml - 1 and 0 . 5 nmol [ 358 ] PAPS ( specific 
sulfation . The conversion of compound 4 to 5 was com - activity of [ 355 ] PAPS was 2 . 2x104 cpm / pmol ) , oligosaccha 
pleted by 3 - O - sulfation using 3 - OST - 5 enzyme . The 6 - O - ride 5 ug in total 500 ul at 37° C . overnight . 35S - labeled 
sulfation reaction contained 50 mM MES , PH 7 . 0 , 1 . 5 mM LMWH Compounds 5 was prepared from LMWH Com 
PAPS and 0 . 3 mM substrate , 0 . 2 mgml - 1 6 - OST - 1 and 0 . 2 20 pounds 4 . Reaction consisted of MES 50 mM pH 7 . 0 , 10 
mgml - 6 - OST - 3 in 20 to 40 ml overnight at 37° C . The mM MnCl2 , 5 mM MgCl2 , 3 - OST - 5 0 . 1 mgml - 1 and 0 . 5 
extent reaction was monitored by DEAE - HPLC . 3 - OST - 1 nmol [ S ] PAPS ( specific activity of [ S ] PAPS was 2 . 2x 
and 3 - OST - 5 sulfation reaction mixture contained 50 mM 10 * cpm / pmol ) , oligosaccharide 5 ug in total 500 ul at 37° 
MES , PH 7 . 0 , 10 mM MnCi , , 5 mM MgCl2 , 0 . 5 mM PAPS , C . overnight . The ?S - labeled compound 5 was purified by 
0 . 25 mM substrate , 10 ugm1 - 1 3 - OST - 1 or 10 ugml - 1 25 a D - 1 as a DEAE - HPLC column . 
3 - OST - 5 for overnight at 37° C . The extent reaction was also 
monitored by DEAE - HPLC . The products were purified by Example 4 
Q - Sepharose column . 
Example 2 20 Determination of the Binding Affinity of LMWHs 
to Antithrombin ( AT ) 
Purification of Intermediate and LMWH 
Compounds by Q - Sepharose The dissociation constant ( Kg ) of each sample and AT was determined using affinity co - electrophoresis ( Lee , M . K . & 
Purification of Compounds 6 , 7 , 8 , and 9 as well as all the 35 Lander , A . D . , Proc . Natl . Acad . Sci . USA 88 , 2768 - 2772 , 
other earlier intermediate was conducted by a fast flow 1991 ) . Approximately 1500 - 2500 cpm of 35S - labeled 
0 - Sepharose column ( 15x200 mm ; GE Health Care , Wau - LMWH Compounds 1 to 5 was loaded per lane with zones 
watosa , Wis . , United States of America ) , which was eluted of AT at concentrations 0 , 8 , 16 , 32 , 60 , 120 , 250 , 500 and 
with a linear gradient of 20 - 100 % IM NaCl in 20 mM 1000 nM . The gel was performed at 300 mA for 2 h , dried 
NaoAc at pH 5 . 0 in 2 h at a flow rate of 2 mlmin - 1 . 40 and analyzed on a Phospholmager ( Amersham Biosciences , 
Purification of those highly sulfated oligosaccharides , i . e . Wauwatosa , Wis . , United States of America Storm 860 ) . The 
LMWH Compounds 1 - 5 , was carried out by a Q - Sepharose retardation coefficient was calculated at R = ( Mo - M ) / Mo , 
column , which was eluted with a linear gradient of 30 - 100 % where M , is the mobility of the polysaccharide through the 
2M NaCl in 20 mM NaOAc at pH 5 . 0 in 2 h at a flow rate zone without AT , and M is the mobility of the sample 
of 2 mlmin - 1 . 45 through each separation zone . The retardation coefficient 
Determination of the in vitro and ex vivo anti - Xa activity . was then plotted against the retardation coefficient divided 
Assays were based on a previously published method by its respective concentration of AT . The slope of the line 
( Zhang , L . et al . , J . Biol . Chem . 276 , 42311 - 42321 , 2001 ; represents – 1 / K? : 
Duncan et al . , Biochim Biophys Acta 1671 , 34 - 43 , 2004 ) . 
Briefly , human factor Xa ( Enzyme Research Laboratories , 50 Example 5 
South Bend , Ind . , United States of America ) was diluted to 
50 Uml - 1 with PBS . The chromogenic substrates , S - 2765 
was from Diapharma ( Westchester , Ohio , United States of Neutralization of LMWHS by Protamine In Vitro 
America ) and made up at 1 mgml - 1 in water . UFH ( from US 
Pharmacopea ) , LOVENOX® ( from local pharmacy ) and 55 The procedures followed a previous publication 
LMWH Compounds 1 to 5 ) was dissolved in PBS at various ( Sundaram , M . et al . , Proc . Natl . Acad . Sci . 100 , 651 - 656 , 
concentrations ( 3 to 600 ugml - ? ) . The reaction mixture , 2003 ) . The LMWH Compounds and protamine chloride 
which consisted of 20 ul of human plasma ( Sigma - Aldrich , ( Sigma - Aldrich ) were dissolved in PBS . The concentrations 
St . Louis , Mo . , United States of America ) and 8 ul of the of the LMWH samples for each Compound were different 
solution containing the sample , was incubated at room 60 because each Compound has different IC50 value for the 
temperature for 5 min . Factor Xa ( 100 ul ) was then added . anti - Xa activity . The reaction mixture consisted of 20 ul of 
After incubating at room temperature for 4 min , 30 ul of human plasma ( Sigma - Aldrich ) , 2 ul of the stock solution of 
S - 2765 substrate was added . The absorbance of the reaction LMWHs ( 400xIC50 of its anti - Xa activity ) and 8 ul of 
mixture was measured at 405 nm continuously for 5 min . protamine with various concentrations ( from 0 - 90 ug / ml ), 
The absorbance values were plotted against the reaction 65 and was incubated at room temperature for 5 min . The 
time . The initial reaction rates as a function of concentration mixture ( 30 ul ) was then subjected to anti - Xa activity 
were used to calculate the IC50 values . measurement as described above . 
38 
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Example 6 America ) was used to introduce the sample by direct infu 
sion ( 35 ulmin - ) . Experiments were carried out in negative 
Neutralization of LMWHs by Protamine in Mice ionization mode with the electrospray source set to 5 KV and 
275° C . Sulfated oligosaccharide ( 1 ul ) was diluted in a 
The study was performed on eight week old male C57BL / 5 different working solution containing 200 ul of 70 % acetoni 
6J _ mice ( Jackson Laboratories , Bar Harbor , Me . , United trile and 10 mM imidazole . Experiments for sulfated oli 
States of America ) ( n = 4 per group ) . The mouse experiments gosaccharides were carried out in negative ionization mode 
were approved by the UNC Animal Care and Use Commit - with the electrospray source set to 2 KV and 200° C . The 
tees and complied with National Institutes of Health guide - automatic gain control was set to 1x107 for full scan MS . 
lines . Under isoflurane anesthesia , mice were subcutane - 10 The MS data were acquired and processed using Xcalibur 
ously administered with PBS , UFH ( 3 mgkg - ) , 1 . 3 . 
LOVENOX® ( 3 mgkg - 1 ) or Compound 5 ( 0 . 6 mgkg - 1 ) 30 High resolution ESI - MS analysis was conducted on 
min prior to a protamine administration . Protamine ( 15 Thermo LTQ XL Orbitrap ( Breman , Germany ) under the 
mgkg - 1 ) or phosphate buffer saline ( PBS ) was administered following conditions . A Luna hydrophilic liquid interaction 
intravenously via retro - orbital plexus injection , and 5 min 15 chromatography ( HILIC ) column ( 2 . 0x150 mm ? , 200 Å , 
later blood samples were drawn from the inferior vena cava Phenomenex , Torrance , Calif . , United States of America ) 
into syringes preloaded with 3 . 2 % solution of sodium citrate was used to separate the oligosaccharide mixture . Mobile 
( final volume ratio 9 : 1 ) . To obtain mouse plasma , blood phase A was 5 mM ammonium acetate prepared with high 
samples were centrifuged at 4 , 000 g for 15 min at 4° C . performance liquid chromatography ( HPLC ) grade water . 
Mouse plasma was then used to determine anti - Xa activity . 20 Mobile B was 5 mM ammonium acetate prepared in 98 % 
Ex vivo analysis of anti - Xa activity was done similar to the HPLC grade acetonitrile with 2 % of HPLC grade water . 
in vitro study described above . Briefly , plasma ( 10 ul ) from After injection of 8 . 0 uL oligosaccharide mixture ( 1 . 0 uguL 
different groups of mice was incubated with 80 nM human 1 ) through an Agilent 1200 autosampler , HPLC binary pump 
factor Xa ( 10 ul ) at room temperature for 4 minutes and was used to deliver the gradient from 10 % A to 35 % A over 
S - 2765 ( 1 mgml - ? , 30 ul ) was then added . The anti - Xa 25 40 min at a flow rate of 150 uLmin - 1 . The LC column was 
activity in the mouse plasma from the PBS injected mice directly connected online to the standard electrospray ion 
was defined as 100 % . Statistical analysis for multiple com - ization source of LTQ - Orbitrap XL Fourier transform ( FT ) 
parisons was performed by two - way ANOVA with Bonfer mass spectrometer ( MS ) ( Thermo Fisher Scientific , San 
roni ' s post - hoc test ( GraphPad Prism Software , La Jolla , Jose , Calif . , United States of America ) . The source param 
Calif . , United States of America ) . 30 eters for FT - MS detection were optimized using Arixtra® ( purchased at a pharmacy ) to minimize the insource frag 
Example 7 mentation and sulfate loss and maximize the signal / noise in 
the negative - ion mode . The optimized parameters , used to 
Mouse Model of Tail Bleeding prevent in - source fragmentation , included a spray voltage of 
35 4 . 2 kV , a capillary voltage of - 40 V , a tube lens voltage of 
Under isoflurane anesthesia , mice ( n = 8 per group ) were - 50 V , a capillary temperature of 275° C . , a sheath flow rate 
administered with PBS or Compound 5 ( 0 . 6 mgkg - ? ) sub of 30 , and an auxiliary gas flow rate of 6 . External calibra 
cutaneously , 30 min later PBS or protamine ( 15 mgkg - 1 ) tion of mass spectra routinely produced a mass accuracy of 
was administered via retro - orbital intravenous injection . better than 3 ppm . All FT mass spectra were acquired at a 
After 5 minutes the distal part of the tail was transected at 40 resolution 60 , 000 with 300 - 2000 Da mass range . 
the constant diameter ( 1 . 5 mm ) , approximately 3 - 4 mm from 
the end . That results in both arterial and venous bleeding . Example 9 
The tail was immediately placed in 15 ml falcon tube 
containing 13 ml of pre - warm PBS ( 37° C . ) and blood loss NMR Analysis 
was observed for 30 min . The primary bleeding time was 45 
defined as the time to the first cessation of bleeding . Sub - LMWH Compounds and intermediates were analyzed by 
sequently , time for each reinitiated bleeding was also 1D ' H - NMR and 2D NMR ( + H - ' H COSY , ' H - 13C HMQC ) . 
recorded , and used to calculate total bleeding time . One All NMR experiments were performed at 298 K on Bruker 
mouse in Compound 5 / protamine group received an inac - Avance II 800 MHz spectrometer with Topsin 2 . 1 software . 
curate protamine injection and was excluded from the study . 50 Samples ( 3 . 0 to 6 . 0 mg ) were each dissolved in 0 . 5 ml D20 
The blood collected in PBS was used to calculate total blood ( 99 . 996 % , Sigma - Aldrich ) and lyophilized three times to 
volume loss . Formic acid was added to samples ( 70 : 30 ratio ) remove the exchangeable protons . The samples were re 
and absorbance was measured at 405 nm . A standard curve dissolved in 0 . 4 ml D 0 and transferred to NMR microtubes 
was generated by mixing 13 ml of PBS with known amounts ( OD 5 mm , Norrell NMR tubes from Sigma Aldrich ) . 1D ' H 
of blood . Statistical analysis between each group was per - 55 NMR experiments were performed with 256 scans and an 
formed by one - way ANOVA ( GraphPad Prism Software , La acquisition time of 850 msec . 2D ' H - H COSY experiments 
Jolla , Calif . , United States of America ) followed by Bon were performed with 16 scans , 1 . 5 sec relaxation delay , and 
ferroni ' s multiple comparison test . 500 millisecond acquisition time . 2D ' H - 13C HMQC experi 
ments were performed with 16 scans , 1 . 5 sec relaxation 
Example 8 60 delay , and 250 millisecond acquisition time . 
The LMWH Compounds and intermediates were also 
MS Analysis analyzed by 1D ' H - NMR , 1D 13 C - NMR and 2D NMR 
( ' H - H COSY , ' H - 13C HSQC ) on Varian Inova 500 MHz 
The low - resolution analyses were performed at a Thermo spectrometer with Vnmry 2 . 2D software . Samples ( 2 . 0 to 5 . 0 
LCQ - Deca . LMWH Compounds and intermediates were 65 mg ) were dissolved in 0 . 5 ml D20 ( 99 . 994 % , Sigma 
directly diluted in 200 ul of 9 : 1 MeOH / H2O . A syringe pump Aldrich ) and lyophilized three times to remove the ( Harvard Apparatus , Holliston , Mass . , United States of exchangeable protons . The samples were re - dissolved in 0 . 5 
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ml D20 and transferred to NMR microtubes ( OD 5 mm , presented as the percentage of CPM in total liver divided by 
Norrell ) . ID ' H - NMR experiments were performed with total CPM injected standard error of 3 - 5 mice per ligand . 
256 scans and an acquisition time of 768 msec . 1D 13C 
NMR experiments were performed with 40 , 000 scans , 1 . 0 REFERENCES 
sec relaxation delay , and an acquisition time of 1 , 000 msec . 5 
2D ' H - H COSY experiments were performed with 48 The references listed below as well as all references cited 
scans , 1 . 8 sec relaxation delay , and 204 msec acquisition in the specification are incorporated herein by reference to 
time . 2D ' H - 13C HSQC experiments were performed with the extent that they supplement , explain , provide a back 
48 scans , 1 . 5 sec relaxation delay , and 256 msec acquisition ground for or teach methodology , techniques and / or com 
time . 10 positions employed herein . 
Aikawa et al . , ( 1999 ) J . Biol . Chem . 274 , 2690 . 
Example 10 Aikawa , J . - I . , et al . , ( 2001 ) J . Biol . Chem . 276 , 5876 - 5882 . 
Alexander , C . M . , et al . , ( 2000 ) Nat . Genet . 25 , 329 - 332 . 
Determination of the Binding of LMWHs to Altschul et al . ( 1990 ) J Mol Biol 215 , 403 - 410 . 
Stabilin - 2 15 Atha , D . H . , et al . , ( 1985 ) Biochemistry 24 , 6723 - 6729 . 
Avci , F . Y . , et al . , ( 2003 ) Curr . Pharm . Des . 9 , 2323 - 2335 . 
The Stabilin - 2 cell line expressing the 190 - HARE ( Harris Balagurunathan , K . , et al . , ( 2003 ) J . Biol . Chem . 278 , 
et al . , J . Biol . Chem . 279 , 36201 - 36209 , 2004 ) was grown to 52613 - 52621 . 
90 % confluency with DMEM + 8 % FBS + 50 ugml - 1 Hygro - Balagurunathan , K . , et al . , ( 2003 ) Nat . Biotechnol . 21 , 
mycin B in 24 - well plates for at least 2 days prior to the 20 1343 - 1346 . 
experiment in a standard tissue culture incubator . Endocy - Bernfield , M . , et al . , ( 1999 ) Annu . Rev . Biochem . 68 , 729 
tosis medium ( DMEM + 0 . 05 % BSA ) containing a known 777 . 
amount of 35S - labeled LMWH Compound , LOVENOX? . Bjornsson , S . ( 1993 ) Anal . Biochem . 210 , 282 - 291 . 
or UFH was added to each well in triplicate and allowed to Bowman et al . , ( 1999 ) Chem . Biol . 6 , R9 - R22 . 
incubate with the cells for 3 h at 37° C . , 5 % CO . Receptor 25 Burkart , M . D . , et al . , ( 2000 ) J . Org . Chem . 65 , 5565 - 5574 . 
specific internalization was assessed by incubating each Capila , I . , and Linhardt , R . J . ( 2002 ) Angew . Chem . Int . Ed . 
radiolabeled ligand with at least a 100 - fold excess of unla 41 , 390 - 412 . 
beled UFH . The cells were then washed with Hank ' s Bal Carfi , A . , et al . , ( 2001 ) Mol . Cell 8 : 169 - 179 . 
anced Salt Solution ( 1 . 26 mM CaC12 , 5 . 33 mM KC1 , 0 . 44 Chen et al . , ( 1992 ) Protein Expression Purif . 3 , 421 - 6 . 
mM KH PO , 0 . 5 mM MgC1 , - 6H , 0 , 0 . 41 mM MgSO , - 30 Chen , J . , et al . , ( 2003 ) Glycobiology 13 , 785 - 794 . 
7H , O , 138 mM NaCl , 4 . 0 mM NaHCO3 , 0 . 3 Na , HPO4 , 0 . 3 Chen et al . , ( 2005 ) J . Biol . Chem . 280 , 42817 - 42825 . 
mM phenol red , pH 7 . 2 ) three - times , and cells were lysed in Conrad , H . ( 1998 ) Heparin - binding Proteins , Academic 
0 . 4 ml 0 . 3 N NaOH . 0 . 35 ml of the cell lysate mixture was Press , San Diego , Calif . 
mixed with 4 ml scintillation fluid ( Perkin Elmer , Waltham , Copeland et al . , ( 2008 ) Biochemistry 47 : 5774 - 5783 . 
Mass . , United States of America ) and radioactivity was 35 Das et al . ( 2001 ) Chemistry 7 , 4821 - 4834 . 
measured by a Beckman Coulter LS6500 scintillation coun - Dementiev , A . , et al . , ( 2004 ) Nat . Struct . Biol . 11 , 867 - 863 . 
ter . The remaining 0 . 05 ml cell lysate was used to determine Dooley ( 1998 ) Chemico - Biol . Interact . 109 , 29 . 
protein levels using the Bradford reagent ( Sigma - Aldrich ) . Duncan , M . B . , et al . , ( 2004 ) Biochim . Biophys . Acta 1671 , 
The data was calculated as the percentage of specific CPM 34 - 43 . 
internalized of the total amount added per ug cell lysate 40 Edavettal , S . C . , et al . , ( 2004 ) J . Biol . Chem . 279 , 25789 
protein standard deviation . 25797 . 
Esko , J . D . , and Lindahl , U . ( 2001 ) J . Clin . Invest . 108 : 169 
Example 11 
Esko , J . D . , and Selleck , S . B . ( 2002 ) Annu . Rev . Biochem . 
Determination of the Clearance of LMWHs In Vivo 45 71 , 435 - 471 . 
Falany ( 1997 ) FASEB J . 11 , 1 - 2 . 
The mouse experiment was approved by the University of Feyerabend et al . ( 2006 ) Nat . Chem . Biol . 2 , 195 - 196 . 
Nebraska Animal Care and Use Committees . Five to six Fukuta et al . ( 1998 ) Biochim . Biophys . Act . 1399 , 57 . 
week old BALB / c mice ( Harlan Laboratories , Indianapolis , Fuster et al . ( 2005 ) Nat . Rev . Cancer 5 , 526 - 542 . 
Ind . , United States of America ) weighing 18 - 20 g were 50 Gama et al . ( 2006 ) Nat . Chem . Biol . 2 , 467 - 473 . 
anesthetized in a small 34° C . chamber with a flow of Gribskov et al . ( 1986 ) Nuc Acids Res 14 ( 1 ) , 327 - 334 . 
oxygen containing 4 % isoflurane . Once the mice were Guo et al . ( 1994 ) Chem . Biol . Interact . 92 , 25 - 31 . 
unconscious , they were individually placed on a heated pad Habuchi et al . , ( 1998 ) J . Biol . Chem . 273 , 9208 . 
with a nose cone fitted over their snout with a constant flow Habuchi , H . , et al . , ( 2000 ) J . Biol . Chem . 275 , 2859 - 2868 . 
of oxygen containing 2 % isoflurane . A specific amount of 55 Harris , E . N . et al . , J . Biol . Chem . 279 , 36201 - 36209 ( 2004 ) . 
35S - labeled LMWH Compound , LMWH , or UFH was Kakuta et al . ( 2003 ) Biochem . Soc . Trans . 31 ( pt2 ) , 331 - 334 . 
injected via the lateral tail vein using a 27G1 / 2 needle Kreuger et al . ( 2006 ) J . Cell Biol . 174 , 323 - 327 . 
mounted on a 1 ml syringe . The labeled material was Krummenacher , C . , et al . , ( 1999 ) J . Virol . 73 , 8127 - 8137 . 
allowed to circulate in the blood for 12 min while the mouse Kuberan , B . , et al . , ( 2003 ) J . Am . Chem . Soc . 125 , 12424 
lay unconscious . The abdominal cavity was exposed by 60 12425 . 
incision and the liver was collected , washed , and weighed . Kyte et al . ( 1982 ) J Mol Biol 157 , 105 . 
Approximately 100 mg from each of the lobes was homog - Lee , M . K . , and Lander , A . D . , ( 1991 ) Proc . Natl . Acad . Sci . 
enized in 0 . 75 ml 1 % NP - 40 and then centrifuged at USA 88 , 2768 - 2772 . 
12 , 000xg for 2 min to pellet insoluble material . The super - Li et al . ( 1997 ) J . Biol . Chem . 272 , 28158 - 28163 
natant was then added to 4 ml scintillation fluid , mixed for 65 Lin et al . , ( 1995 ) J . Am . Chem . Soc . 117 , 8031 . 
30 min by rocking and then radioactivity was assessed by a Lin et al . ( 1998 ) Anal . Biochem . 264 , 111 - 117 . 
Beckman Coulter LS6500 scintillation counter . The data is Lindahl , U . , et al . , ( 1998 ) J . Biol . Chem . 273 , 24979 - 24982 . 
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Lindahl , U . et al . , ( 2005 ) J . Med . Chem . 48 , 349 - 352 . Zhang , L . , et al . , ( 2001 ) J . Biol . Chem . 276 , 42311 - 42321 . 
Linhardt , R . J . ( 2003 ) J . Med . Chem . 46 , 2551 - 2564 . Zhang , L . , et al . , ( 2001 ) J . Biol . Chem . 276 , 28806 - 28813 . 
Liu , J . , and Thorp , S . C . ( 2002 ) Med . Res . Rev . 22 , 1 - 25 . Zhao , G . , et al . , Glycobiology 21 , 771 - 780 ( 2011 ) 
Liu , J . , et al . , ( 1996 ) J . Biol . Chem . 271 , 27072 - 27082 . It will be understood that various details of the presently 
Liu , J . , et al . , ( 1999 ) J . Biol . Chem . 274 , 38155 - 38162 . 5 disclosed subject matter can be changed without departing 
Liu , J . , et al . , ( 1999 ) J . Biol . Chem . 274 , 5185 - 5192 . from the scope of the presently disclosed subject matter . 
Liu , J . , et al . , ( 1999 ) J . Biol . Chem . 274 , 5185 - 5192 . Furthermore , the foregoing description is for the purpose of 
Liu , J . , et al . , ( 1999 ) J . Biol . Chem . 274 , 38155 - 38162 . illustration only , and not for the purpose of limitation . 
Liu , J . , et al . , ( 2002 ) J . Biol . Chem . 277 , 33456 - 33467 . 
Liu , R . et al . J Biol Chem 285 , 34240 - 34249 ( 2010 ) . 10 What is claimed is : 
Liu et al . ( 2007 ) Appl . Microbiol . Biotechnol . 74 , 263 - 272 . 1 . A method of synthesizing a heparin compound , com 
Marcus et al . ( 1980 ) Aial . Biochem . 107 , 296 . prising : providing a monosaccharide substrate ; 
Marshall et al . , ( 1997 ) J . Biol . Chem . 272 , 9153 - 9160 . elongating the monosaccharide substrate to a hexasaccha 
Marshall et al . , ( 1998 ) Chem . Biol . Interact . 109 , 107 - 116 . ride using enzymes N - acetyl glucosaminyl transferase 
Mazany et al . , ( 1998 ) Biochim . Biophys . Act . 1407 , 92 . 15 and heparosan synthase - 2 , and substrates glucuronic 
Moon , A . , et al . , ( 2004 ) J . Biol . Chem . 279 , 45185 - 45193 . acid ( GlcUA ) and N - trifluoroacetyl glucosamine ( Gl 
Muñoz et al . ( 2006 ) Biochemistry 45 , 5122 - 5128 . CNTFA ) ; 
Muñoz et al . ( 2006 ) Biochem . Biophys . Res . Commun . 339 , converting N - trifluoroacetyl glucosamine ( GleNTFA ) 
597 - 602 residue ( s ) on the hexasaccharide to N - sulfo glu 
Nastuk et al . ( 1998 ) J . Neuroscience 18 , 7167 . 20 cosamine ( GlcNS ) residues using N - sulfotransferase 
Needleman et al . ( 1970 ) J Mol Biol 48 , 443 . ( NST ) , 3 ' - phosphoadenosine 5 - phosphosulfate 
Ong et al . , ( 1998 ) J . Biol . Chem . 273 , 5190 . ( PAPS ) , and a base to provide an N - sulfated hexasac 
Ornitz , D . M . , et al . , ( 1996 ) J . Biol . Chem . 271 , 15292 charide substrate ; 
15297 . epimerizing the N - sulfated hexasaccharide substrate 
Ouyang et al . , ( 1998 ) J . Biol . Chem . 273 , 24770 . 25 2 using Cz - epimerase ( Cz - epi ) ; sulfating the resultant 
Ozawa et al . , ( 1990 ) Nucleic Acids Res . 18 , 4001z . epimerized hexasaccharide using 2 - O - sulfotransferase 
Pempe et al . , ( 2012 ) J . Biol . Chem . 287 , 20774 - 20783 . ( 2 - OST ) and 3 ' - phosphoadenosine 5 ' - phosphosulfate 
Petitou , M . , et al . , ( 1999 ) Nature 398 , 417 - 422 . ( PAPS ) to provide the following hexasaccharide sub 
Petitou , M . , and van Boeckel , C . A . A . ( 2004 ) Angew . Chem . strate : 
Int . Ed . 43 , 3118 - 3133 . 
Reizes , O . , et al . , ( 2001 ) Cell 106 : 105 - 116 . 
Rosenberg , R . D . , et al . , ( 1997 ) J . Clin . Invest . 99 , 2062 CH2OSO3H 
2070 . - O 
Saeki et al . ( 1998 ) J . Biochem . 124 , 55 . 
Sambrook et al . ( 2001 ) Molecular Cloning : A Laboratory 35 CH2OSO3H quon NOSO3H / 
- 0 OL Manual , Third Edition , Cold Spring Harbor Laboratory LO 
Press , Cold Spring Harbor , NHSO3H OH New York . LO Sasisekharan , R . , et al . , ( 2002 ) Nat . Rev . Cancer 2 , 521 - 528 . Schwartz et al . ( 1979 ) Nuc Ácids Res 6 ( 2 ) , 745 - 755 . 40 OH NHSO3H OH 
Shively , J . E . , and Conrad , H . E . ( 1976 ) Biochemistry 15 , CH2OSO3H 
3932 - 3942 . 
Shriver et al . ( 2004 ) Nat . Rev . Drug Discov . 863 - 873 . OH Shukla , D . , et al . ( 1999 ) Cell 99 , 13 - 22 . MS 
Shukla , D . , and Spear , P . G . ( 2001 ) J . Clin . Invest . 108 , 45 
503 - 510 . COOH 
Shworak , N . W . , et al . , ( 1997 ) J . Biol . Chem . 272 , 28008 NHSO3H 
28019 . 
Smith et al . ( 1981 ) Adv Appl Math 2 , 482 . OSO3H Sundaram , M . et al . , Proc . Natl . Acad . Sci . 100 , 651 - 656 50 
( 2003 ) 
Thompson et al . ( 1994 ) Nucleic Acids Res 22 ( 22 ) , 4673 wherein MS is a monosaccharide ; 
4680 . elongating the hexasaccharide substrate to a heptasaccha 
U . S . Pat . No . 6 , 255 , 088 ride using heparosan synthase - 2 and glucuronic acid 
U . S . Pat . No . 4 , 554 , 101 . 55 ( GlCUA ) ; 
Uchimura et al . ( 1998 ) J . Biol . Chem . 273 , 22577 . elongating the heptasaccharide to an octasaccharide using 
Vann et al . , ( 1981 ) Eur . J . Biochem . 116 , 359 - 364 . N - acetyl glucosaminyl transferase and - N - trifluoro 
Wethmur & Davidson ( 1968 ) J Mol Biol 31 , 349 - 370 . acetyl glucosamine ( GlcNTFA ) ; epimerizing the resul 
Willis , S . H . , et al . , ( 1998 ) J . Virol . 72 , 5938 - 5947 tant octasaccharide using Cz - epimerase ( Cz - epi ) ; sul 
WuDunn , D . , and Spear , P . G . ( 1989 ) J . Virol . 63 , 52 - 58 . 60 fating the resultant epimerized octasaccharide using 
Xu , D . et al . , Nat Chem Biol 4 , 200 - 202 ( 2008 ) . 2 - 0 - sulfotransferase ( 2 - OST ) and 3 ' - phosphoadenos 
Xu , Y . et al . Science 334 , 498 - 501 ( 2011 ) . ine 5 ' - phosphosulfate ( PAPS ) ; 
Xu , Y . et . al . , Nat Chem Biol 4 , 248 - 252 ( 2014 ) . converting N - trifluoroacetyl glucosamine ( GlcNTFA ) 
Yang et al . ( 1996 ) Protein Expression Purif . 8 , 423 - 429 . residue ( s ) to N - sulfo glucosamine ( GlcNS ) residues 
Yang et al . , ( 1997 ) Protein Eng . 10 , 70 . using N - sulfotransferase ( NST ) , 3 ' - phosphoadenosine 
Yang et al . , ( 1998 ) Chem . - Biol . Interact . 109 , 129 - 135 . 5 ' - phosphosulfate ( PAPS ) , and a base to produce an 
Yoshinari et al . , ( 1998 ) J . Biochem . 123 , 740 . octasaccharide substrate ; 
OH 
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elongating the octasaccharide substrate to a decasaccha wherein R , is H or a detectable tag , 
ride using in the following order : elongating the hexasaccharide to a heptasaccharide using ( 1 ) heparosan synthase - 2 and glucuronic acid ( GICUA ) ; heparosan synthase - 2 and glucuronic acid ( GIUA ) ; 
and elongating the heptasaccharide to an octasaccharide using ( 2 ) N - acetyl glucosaminyl transferase and N - trifluoro - s N - acetyl glucosaminyl transferase and N - trifluoro 
acetyl glucosamine ( GlcNTFA ) ; acetyl glucosamine ( GlcNTFA ) ; 
epimerizing the decasaccharide using C5 - epimerase ( Cs epimerizing the octasaccharide using C5 - epimerase ( C5 
epi ) ; sulfating the resultant epimerized decasaccharide epi ) ; sulfating the resultant epimerized octasaccharide 
using 2 - O - sulfotransferase ( 2 - OST ) and 3 ' - phosphoad - 10 using 2 - 0 - sulfotransferase ( 2 - OST ) and 3 ' - phosphoad 
enosine 5 ' - phosphosulfate ( PAPS ) ; enosine 5 ' - phosphosulfate ( PAPS ) ; 
converting N - trifluoroacetyl glucosamine ( GlcNTFA ) converting N - trifluoroacetyl glucosamine ( GlcNTFA ) 
residue ( s ) on the resultant sulfated decasaccharide to residue ( s ) on the resultant sulfated octasaccharide to 
N - sulfo glucosamine ( GlcNS ) residues using N - sul N - sulfo glucosamine ( GlcNS ) residues using N - sul 
fotransferase ( NST ) , 3 ' - phosphoadenosine 5 ' - phospho - 15 fotransferase ( NST ) , 3 ' - phosphoadenosine 5 ' - phospho 
sulfate ( PAPS ) , and a base to produce a decasaccharide sulfate ( PAPS ) , and a base to provide an octasaccharide 
substrate ; substrate ; 
elongating the decasaccharide substrate to a dodecasa elongating the octasaccharide substrate to a decasaccha 
ccharide using in the following order : ride using heparosan synthase - 2 and N - acetyl glu 
cosaminyl transferase and substrates glucuronic acid 1 ) heparosan synthase - 2 and glucuronic acid ( GICUA ) ; ( GlCUA ) and N - trifluoroacetyl glucosamine ( Gl 
and CNTFA ) ; ( 2 ) N - acetyl glucosaminyl transferase and N - trifluoro 
acetyl glucosamine ( GlcNTFA ) or N - acetylglu epimerizing the decasaccharide using C3 - epimerase ( C5 epi ) ; sulfating the resultant epimerized decasaccharide cosamine ( NACGlc ) ; using 2 - 0 - sulfotransferase ( 2 - OST ) and 3 ' - phosphoad epimerizing the dodecasaccharide using Cs - epimerase enosine 5 ' - phosphosulfate ( PAPS ) ; ( Cz - epi ) ; sulfating the epimerized dodecasaccharide converting N - trifluoroacetyl glucosamine ( GlcNTFA ) by the following reactions : residue ( s ) on the resultant sulfated decasaccharide to ( 1 ) using 2 - 0 - sulfotransferase ( 2 - OST ) and 3 ' - phospho - 20 N - sulfo glucosamine ( GICNS ) residues using N - sul 
adenosine 5 ' - phosphosulfate ( PAPS ) ; fotransferase ( NST ) , 3 ' - phosphoadenosine 5 ' - phospho ( 2 ) using a 6 - O - sulfotransferase ( 6 - OST ) and 3 ' - phospho sulfate ( PAPS ) , and a base to provide a decasaccharide 
adenosine 5 ' - phosphosulfate ( PAPS ) ; and substrate ; ( 3 ) using a 3 - O - sulfotransferase ( 3 - OST ) and 3 ' - phospho elongating the decasaccharide substrate to a dodecasac 
adenosine 5 ' - phosphosulfate ( PAPS ) ; charide using heparosan synthase - 2 and N - acetyl glu 
wherein a heparin compound is synthesized . cosaminyl transferase and substrates glucuronic acid 
2 . The method of claim 1 , wherein the base is lithium ( GICUA ) and N - acetyl glucosamine ( NACGlc ) ; 
hydroxide . epimerizing the dodecasaccharide using Cz - epimerase 
3 . The method of claim 1 , wherein the 6 - O - sulfotrans ( Cs - epi ) ; sulfating the resultant epimerized dodecasa 
ferase ( 6 - OST ) is 6 - O - sulfotransferase 1 and / or 3 ( 6 - OST - * ccharide using : 
land / or 6 - OST - 3 ) . ( 1 ) 2 - 0 - sulfotransferase ( 2 - OST ) and 3 ' - phosphoadenos 
4 . The method of claim 1 , wherein the 3 - OST is 3 - 0 ine 5 ' - phosphosulfate PAPS ) ; 
sulfotransferase - 5 ( 3 - OST - 5 ) . ( 2 ) 6 - O - sulfotransferase 1 and / or 3 ( 6 - OST - 1 and / or 5 . The method of claim 1 , wherein the glycosyl trans - 45 6 - OST - 3 ) , and 3 ' - phosphoadenosine 5 ' - phosphosulfate ferase is selected from the group consisting of N - acetyl ( PAPS ) ; and glucosaminyl transferase of E . coli K5 ( KfiA ) and / or hepa 
rosan synthase - 2 ( pmHS2 ) from Pasteurella multocida . ( 3 ) 3 - O - sulfotransferase 1 ( 3 - OST - 1 ) , and 3 ' - phosphoad 
6 . A method of synthesizing a heparin compound , com enosine 5 ' - phosphosulfate ( PAPS ) ; 
prising : providing a hexasaccharide represented by the fol wherein a heparin compound represented by the following 
lowing structure : structure is synthesized : 
25 
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wherein R2 is H or a detectable tag . 
7 . The method of claim 6 , wherein the synthesized heparin 
compound is a synthetic , low - molecular weight heparin 
compound with reversible anticoagulant activity , wherein 
the anticoagulant activity of the heparin compound is revers 
ible by protamine . 
8 . The method of claim 6 , wherein the base is lithium 
hydroxide . 
30 9 . The method of claim 6 , wherein the glycosyl trans 
ferase is selected from the group consisting of N - acetyl 
glucosaminyl transferase of E . coli K5 ( KfiA ) and / or hepa 
rosan synthase - 2 ( pmHS2 ) from Pasteurella multocida . 
35 10 . The method of claim 6 , wherein the detectable tag is 
para - nitrophenyl . 
11 . A low - molecular weight heparin compound , which is 
a synthesized material , with reversible anticoagulant activ 
ity , represented by the following formula : 
CH2OSO3H 
- O 
COOH 
OH CH2OSO3H COOH OSO3H 
- 0 . O Dube NHSO3H OSO3H OH OH OH OH P3 
CH2OSO3H COOH 
OR ? 
OH CH2OSO3H 
COOH 
OH NHSO3H OH ?? 
NHSO3H OSO3H 
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wherein Rl is independently H or — SOZH , R2 is H or a 
detectable tag , Rºis — NHSO3H or — NHCOCH3 , and 
n is an integer of 0 - 3 . 
12 . The heparin compound of claim 11 , wherein the heparin compound is represented by the following structure : 
HO2SO 
HO2SO 
HOM 
HO HN HOOC HOOC HO3SO 
HO , SO 0 OH ?o . ???? OH o = ? 
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HOOC HO3SO 
HO HN 
HOOC HO3SO 
HO3S 
HN OH 
HO3SÓ HO3S HOOC HO HN 
HO3SÓ O HO 
HO3S OH 
35 wherein R2 is H or a detectable tag . 
13 . The heparin compound of claim 11 , wherein the 
heparin compound is represented by the following structure : 
HO3SO 
6a / 6b HO3SO 
6a / 6b HO5 
HOOC 
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HO 4 3 OOC 
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HO2SO 3 6a / 6b HN 4 
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wherein R , is H or a detectable tag . 
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14 . The heparin compound of claim 11 , wherein the 18 . The method of claim 17 , wherein the subject suffers 
heparin compound comprises at least one 3 - 0 sulfate . from venous thromboembolism . 
15 . The heparin compound of claim 11 , wherein the 19 . The method of claim 17 , wherein the subject is 
heparin compound is a dodecamer . renal - impaired . 
16 . The heparin compound of claim ll , wherein the 5 20 . A method of treating a subiect in need of anticoagulant detectable tag is paranitrophenyl . 
17 . A method of treating a subject , the method compris therapy , the method comprising : ing : providing a subject in need of anticoagulant therapy ; 
providing a subject to be treated ; administering to the subject a heparin compound having 
administering to the subject a heparin compound having anticoagulant activity ; monitoring the subject for hepa 
anticoagulant activity , wherein the heparin compound rin - induced thrombocytopenia ; and administering to 
is selected from : the subject an antidote to reverse the anticoagulant 
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wherein R2 is H or a detectable tag , and wherein the 65 
anticoagulant activity of the heparin compound is 
reversible by protamine . 
activity of the heparin compound if the subject suffers 
from heparin - induced thrombocytopenia , wherein the 
heparin compound is selected from : 
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wherein R2 is H or a detectable tag . 
21 . The method of claim 20 , wherein the antidote to 55 
reverse the anticoagulant activity of the heparin compound 
is protamine . 
* * * * * 
